[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 433
1. Oriol A, Ribera JM, Bergua J, Giménez Mesa E, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L, Hernandez-Rivas JM, Hoelzer D: High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer; 2008 Jul 1;113(1):117-25
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.
  • BACKGROUND: It has been recognized that cure is possible for human immunodeficiency virus (HIV)-infected patients with Burkitt lymphoma/leukemia (BL) if appropriate chemotherapy is used.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Drug Administration Schedule. Feasibility Studies. Female. Humans. Immunotherapy. Male. Middle Aged. Remission Induction. Rituximab. Survival Analysis

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 American Cancer Society.
  • (PMID = 18457327.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


2. Aldoss IT, Weisenburger DD, Fu K, Chan WC, Vose JM, Bierman PJ, Bociek RG, Armitage JO: Adult Burkitt lymphoma: advances in diagnosis and treatment. Oncology (Williston Park); 2008 Nov 30;22(13):1508-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt lymphoma: advances in diagnosis and treatment.
  • Burkitt lymphoma is a unique B-cell malignancy with a high proliferation rate and characteristic genetic changes involving the c-myc oncogene.
  • Burkitt lymphoma is common in children but also occurs in adults, where distinction from diffuse large B-cell lymphoma may pose a problem.
  • The development of brief, very intensive chemotherapy regimens has led to a very high cure rate in children with Burkitt lymphoma.
  • Burkitt lymphoma in adults cannot be treated effectively with the common regimens used for diffuse large B-cell lymphoma such as CHOP-R (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone, rituximab).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Clinical Trials, Phase II as Topic. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Genes, myc. Humans. Ifosfamide / administration & dosage. Leucovorin / administration & dosage. Methotrexate / administration & dosage. Practice Guidelines as Topic. Prednisone / administration & dosage. Prognosis. Rituximab. Stem Cell Transplantation / methods. Survival Analysis. Teniposide / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Oncology (Williston Park). 2008 Nov 30;22(13):1518-9 [19227573.001]
  • [CommentOn] Oncology (Williston Park). 2008 Nov 30;22(13):1519, 1522-3 [19227574.001]
  • (PMID = 19133605.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 957E6438QA / Teniposide; Q573I9DVLP / Leucovorin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 89
  •  go-up   go-down


3. Magri K, Riethmuller D, Maillet R: [Pelvic Burkitt lymphoma mimicking an ovarian tumor]. J Gynecol Obstet Biol Reprod (Paris); 2006 May;35(3):280-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic Burkitt lymphoma mimicking an ovarian tumor].
  • [Transliterated title] Lymphome de Burkitt pelvien simulant un cancer de l'ovaire.
  • Primary malignant lymphoma of the ovary is a rare tumor (1,5% of ovarian tumors).
  • Burkitt lymphoma, is sporadic in western countries, usually with abdominal involvement.
  • We report a case of a young woman who developed abdominal Burkitt Lymphoma mimicking advanced-stage bilateral ovarian cancer.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. Cytarabine / therapeutic use. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Methotrexate / therapeutic use. Pelvic Pain / etiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645563.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Coche D, Bergues B, Harrivel V, Guillaume N: [Biphenotypic acute leukaemia with Burkitt-like cytology]. Ann Biol Clin (Paris); 2009 Jul-Aug;67(4):437-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biphenotypic acute leukaemia with Burkitt-like cytology].
  • [Transliterated title] Leucémie aiguë biphénotypique avec aspect cytologique de type Burkitt.
  • Biphenotypic acute leukaemia (BAL) represents about 5% of adult acute leukaemia.
  • Here, we report the case of a BAL with Burkitt-like cytology, corresponding to "the acute lymphoblastic leukaemia, Burkitt type" L3 for the FAB classification.
  • [MeSH-minor] Adult. Blast Crisis / pathology. Burkitt Lymphoma / pathology. Flow Cytometry / methods. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19654084.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Perkins AS, Friedberg JW: Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program; 2008;:341-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in adults.
  • This review will begin with a detail of the revision of the WHO classification, and pathological definitions of Burkitt lymphoma.
  • Over the past several years, molecular understanding of Burkitt lymphoma has improved significantly.
  • Using gene expression profiling, a genomic "signature" of Burkitt lymphoma may be identified, that has fidelity beyond c-myc expression, and the presence of the classical t(8;14).
  • Then, evaluation and therapy of the adult patient with Burkitt lymphoma will be reviewed.
  • Relatively few data exist on optimal therapy of the adult patient with Burkitt lymphoma.
  • The outcome of adult patients with Burkitt lymphoma, particularly those over 40 years of age, is inferior to the outcome of younger patients, but may be improving over the past few years.
  • Results from an international collaborative effort, which are helpful in evaluating results of Burkitt lymphoma therapy in adults, will be presented.
  • HIV-associated Burkitt lymphoma, and elderly patients with Burkitt lymphoma, comprise special clinical situations that will be also covered in this review.

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074108.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


6. Ng SP, Leong CF, Nurismah MI, Shahila T, Jamil MA: Primary Burkitt lymphoma of the ovary. Med J Malaysia; 2006 Aug;61(3):363-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Burkitt lymphoma of the ovary.
  • Histopathology report confirmed Burkitt lymphoma of ovary.
  • There was no other evidence of lymphoma elsewhere.
  • The primary Burkitt lymphoma of the ovaries was successfully managed with six courses of highly toxic chemotherapy (Berlin-Frankfurt- Munster 1986 protocol).
  • [MeSH-major] Burkitt Lymphoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17240592.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


7. Song KW, Barnett MJ, Gascoyne RD, Horsman DE, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Voss NJ, Toze CL, Connors JM: Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol; 2006 Jun;133(6):634-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma.
  • High dose chemoradiotherapy and haematopoietic stem cell transplantation (SCT) is used as primary therapy for patients diagnosed with Burkitt lymphoma (BL).
  • [MeSH-major] Burkitt Lymphoma / therapy. Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704438.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Troxell ML, Bangs CD, Cherry AM, Natkunam Y, Kong CS: Cytologic diagnosis of Burkitt lymphoma. Cancer; 2005 Oct 25;105(5):310-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic diagnosis of Burkitt lymphoma.
  • BACKGROUND: The diagnosis and classification of lymphoma require correlation of morphologic, immunophenotypic, and molecular-cytogenetic studies.
  • METHODS: The authors report a series of seven cases clinically or morphologically suspicious for Burkitt lymphoma.
  • However, only three of these cases represented Burkitt lymphoma, with one additional case of atypical Burkitt lymphoma.
  • The other cases included diffuse large B-cell lymphoma, monomorphic posttransplant B-cell lymphoma, and an aggressive B-cell lymphoma, with the latter case negative for c-myc rearrangement by FISH.
  • Of 2 non-Burkitt lymphoma specimens tested, 1 was positive for the immunoglobulin H/bcl-2 rearrangement, in addition to the c-myc rearrangement, suggesting transformation from a lower grade lymphoma.
  • CONCLUSIONS: These cases illustrated the value of FNAB in the diagnosis of Burkitt lymphoma, as well as the importance of obtaining material for, and integrating results of, ancillary studies for the final diagnosis.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Genes, myb / genetics
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Diagnosis, Differential. Female. Flow Cytometry. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Sensitivity and Specificity. Specimen Handling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986398.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Kelemen K, Braziel RM, Gatter K, Bakke TC, Olson S, Fan G: Immunophenotypic variations of Burkitt lymphoma. Am J Clin Pathol; 2010 Jul;134(1):127-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic variations of Burkitt lymphoma.
  • Burkitt lymphoma (BL) exhibits a characteristic immunophenotype that is positive for pan-B-cell antigens and CD10 and expresses clonal surface immunoglobulins (SIgs).
  • We evaluated 35 BLs and identified atypical immunophenotypes in 4 including SIg light chain negativity in 4, negativity for B-cell antigens in 2, lack of CD10 in 1, and CD4 expression in 1.
  • [MeSH-major] Burkitt Lymphoma / immunology. Immunophenotyping. Lymphoma, AIDS-Related / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Chromosome Aberrations. Female. Flow Cytometry. Humans. Immunoglobulin kappa-Chains / genetics. In Situ Hybridization, Fluorescence. Male. Middle Aged. Remission Induction. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551277.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


10. Bociek RG: Adult Burkitt's lymphoma. Clin Lymphoma; 2005 Jun;6(1):11-20
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt's lymphoma.
  • Burkitt's lymphoma is a mature B-cell lymphoma that is characterized by a rapid proliferative rate and propensity for extranodal sites of involvement such as the gastrointestinal tract and central nervous system.
  • This subtype of non-Hodgkin's lymphoma is associated with unique cytogenetic translocations involving the c-MYC oncogene on chromosome 8, which appears to be involved in the pathogenesis of this disease.
  • Although current literature is limited by a lack of randomized trials, Burkitt's lymphoma appears to be curable in a high proportion of cases if treated with aggressive multiagent chemotherapy regimens.
  • The use of autologous stem cell transplantation appears to benefit patients who have had chemotherapy-sensitive relapses.
  • The role of allogeneic stem cell transplantation for this disease remains uncertain.
  • Patients with HIV-associated Burkitt's lymphoma appear to have a better prognosis today, which is likely a result of more effective antiretroviral therapy and the ability to treat selected patients with more aggressive chemotherapeutic regimens than before.
  • This article will review the epidemiologic, biologic, diagnostic, and therapeutic aspects of Burkitt's lymphoma in adults.
  • [MeSH-major] Burkitt Lymphoma
  • [MeSH-minor] Adult. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989701.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


11. Vu H, Vildor E, Reddy S, Phillips J, Meenrajan S, Edwards L, Hosenpud J: An unusual presentation of Burkitt lymphoma. South Med J; 2009 Sep;102(9):961-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of Burkitt lymphoma.
  • We describe a 37-year-old non-smoker who presented with dyspnea and a unilateral effusion secondary to Burkitt lymphoma (BL).
  • Burkitt lymphoma is discussed.
  • [MeSH-major] Burkitt Lymphoma / complications. Burkitt Lymphoma / diagnosis. Pleural Effusion, Malignant / etiology
  • [MeSH-minor] Adult. Biopsy. Dyspnea / etiology. Humans. Male. Thoracic Surgery, Video-Assisted

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19668043.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Unholzer A, Starz H, Hirschsteiner O, Balda BR: [Gingival Burkitt lymphoma in a hepatitis C-positive renal transplant patient]. J Dtsch Dermatol Ges; 2005 Jan;3(1):46-51
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gingival Burkitt lymphoma in a hepatitis C-positive renal transplant patient].
  • [Transliterated title] Burkitt-Lymphom der Gingiva bei einem Hepatitis C-positiven nierentransplantierten Patienten.
  • Compared to the general population, the organ transplant patients have a 30-60 fold increased risk of developing non-Hodgkin's lymphoma.
  • A 55-year-old, hepatitis C-positive man developed an Epstein-Barr virus (EBV)- negative Burkitt lymphoma (BL) first appearing on the gingiva under immunosuppressive therapy nine years after allogenic renal transplantation.
  • [MeSH-major] Burkitt Lymphoma / etiology. Gingival Neoplasms / etiology. Hepatitis C / complications. Immunocompromised Host. Kidney Transplantation
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Gingiva / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Time Factors. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353750.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Chennupati SK, Govindaraj S, Setzen G, Chiu AG: Adult Burkitt lymphoma originating in the sphenoid sinus: case report and review of the literature. Ear Nose Throat J; 2009 Jul;88(7):E07

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt lymphoma originating in the sphenoid sinus: case report and review of the literature.
  • Burkitt lymphoma is a high-grade B-cell non-Hodgkin lymphoma.
  • The presence of any type of lymphoma in the paranasal sinuses is rare.
  • We report a case of Burkitt lymphoma that originated in the sphenoid sinus in a 66-year-old white woman.
  • An endoscopic sphenoidotomy was performed to obtain a tissue specimen, and a diagnosis of sporadic Burkitt lymphoma was established on the basis of its clinical, morphologic, and immunohistochemical characteristics.
  • This case is one of the few reported cases of true adult Burkitt lymphoma originating in the sphenoid sinus.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Paranasal Sinus Neoplasms / diagnosis. Sphenoid Sinus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623516.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


14. Cheson BD: Adult Burkitt lymphoma: too soon to declare victory. Oncology (Williston Park); 2008 Nov 30;22(13):1518-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt lymphoma: too soon to declare victory.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Humans. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2008 Nov 30;22(13):1508-17 [19133605.001]
  • (PMID = 19227573.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Muñoz Martín AJ, Pérez Fernández R, Viñuela Beneítez MC, Martínez Marín V, Marquéz-Rodas I, Sabin Domínguez P, García Alfonso P: Primary ovarian Burkitt lymphoma. Clin Transl Oncol; 2008 Oct;10(10):673-5
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian Burkitt lymphoma.
  • Primary ovarian Burkitt lymphoma (BL) is a rare neoplasm in adults.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Female. Humans. Rituximab

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:337-43 [16515618.001]
  • [Cites] Taiwan J Obstet Gynecol. 2006 Jun;45(2):162-6 [17197360.001]
  • (PMID = 18940750.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


16. Kenkre VP, Stock W: Burkitt lymphoma/leukemia: improving prognosis. Clin Lymphoma Myeloma; 2009;9 Suppl 3:S231-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma/leukemia: improving prognosis.
  • Burkitt lymphoma/leukemia (BL) has become a very curable mature B-cell neoplasm.
  • The more widespread use of highly active antiretroviral therapy in the HIV patient with BL has allowed the use of similar aggressive therapies that are used for the non-HIV BL patients, with commensurate improvements in outcomes in this high-risk population.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / therapy. Gene Expression Regulation, Neoplastic. Leukemia / diagnosis. Leukemia / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antiretroviral Therapy, Highly Active. Child. Clinical Trials as Topic. Gene Expression Profiling. HIV Infections / complications. HIV Infections / drug therapy. Humans. Medical Oncology. Prognosis. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778846.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 47
  •  go-up   go-down


17. Abid M, Frikha MF, Mdhaffar M, Mzali R, Ben Amar M, Beyrouti MI: [Two pelvic tumors which should not be operated, lymphoma of Burkitt and actinomycosis]. J Chir (Paris); 2009 Jun;146(3):297-300
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two pelvic tumors which should not be operated, lymphoma of Burkitt and actinomycosis].
  • [Transliterated title] Le lymphome de Burkitt et l'actinomycose, deux tumeurs pelviennes qu'il ne faut pas opérer.
  • [MeSH-major] Actinomycosis / therapy. Anus Neoplasms / therapy. Burkitt Lymphoma / therapy. Pelvis
  • [MeSH-minor] Adult. Female. Humans. Male. Young Adult

  • Genetic Alliance. consumer health - Anaerobic Actinomyces Infection.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19665710.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


18. Pettey AA, Walsh JS: Cutaneous involvement with Burkitt-like lymphoma. Am J Dermatopathol; 2007 Apr;29(2):184-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous involvement with Burkitt-like lymphoma.
  • We report a case of a 27-year-old woman with a known history of Burkitt-like lymphoma (BLL), who presented with a rapidly enlarging nodule in the suprapubic area.
  • BLL is a highly aggressive B-cell lymphoma with a high proliferative rate.
  • Like Burkitt lymphoma, BLL is characterized by a translocation of the c-MYC proto-oncogene.
  • Histopathologic characteristics are considered borderline between those of classic Burkitt lymphoma and diffuse large B-cell lymphoma.
  • [MeSH-major] Burkitt Lymphoma / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD79 / analysis. Female. Gene Expression Regulation, Neoplastic. Genes, myc. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Lymphocytes / immunology. Lymphocytes / pathology. Neoplasm Invasiveness. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414444.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD79; 0 / CD79A protein, human; 0 / Ki-67 Antigen
  •  go-up   go-down


19. Keller C, Savage DG, Rusta-Villa M, Bhagat G, Alobeid B: Primary Burkitt lymphoma of the uterine corpus. Leuk Lymphoma; 2006 Jan;47(1):141-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Burkitt lymphoma of the uterine corpus.
  • This study reports the first well-documented case of sporadic Burkitt lymphoma arising in and confined to the uterine corpus in a 40-year-old woman who presented with vaginal bleeding.
  • Endometrial curettings showed a diffuse infiltrate of medium sized lymphocytes with the characteristic morphologic and immunophenotypic features of Burkitt lymphoma.
  • This report demonstrates that Burkitt lymphoma can present as isolated, organ confined disease at unusual sites and with protean symptoms.
  • [MeSH-major] Burkitt Lymphoma / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 8 / genetics. Female. Humans. Hysterectomy. In Situ Hybridization, Fluorescence / methods. Sensitivity and Specificity. Translocation, Genetic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321839.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Hoffmann C, Wolf E, Wyen C, Fätkenheuer G, Van Lunzen J, Stellbrink HJ, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hentrich M, Goekbuget N, Hoelzer D, Horst HA: AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma; 2006 Sep;47(9):1872-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.
  • The objective was to evaluate the feasibility and efficacy of a short-term, multi-agent and dose intensive regimen in AIDS patients with Burkitt or Burkitt-like lymphoma (BL/BLL) and to compare its efficacy with that of a conventional regimen.
  • Group A received a protocol which was adapted from the German multi-center study group for adult acute lymphoblastic leukemia (GMALL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adult. Antiretroviral Therapy, Highly Active. Cohort Studies. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Doxorubicin / therapeutic use. Drug Therapy, Combination. Feasibility Studies. Female. Humans. Male. Prednisolone / administration & dosage. Prednisone / therapeutic use. Prognosis. Prospective Studies. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065000.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; CHOP protocol
  •  go-up   go-down


21. de Leval L, Hasserjian RP: Diffuse large B-cell lymphomas and burkitt lymphoma. Hematol Oncol Clin North Am; 2009 Aug;23(4):791-827
Genetic Alliance. consumer health - B-Cell Lymphomas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphomas and burkitt lymphoma.
  • Diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphoma (BL) account for the majority of aggressive lymphomas in adults and children.
  • In this article, the authors summarize the recent advances pertaining to these B-cell neoplasms, following the latest World Health Organization classification and focusing on changes introduced since the previous edition.
  • These changes include the addition of variants and subgroups of DLBCLs and "borderline" categories for high-grade B-cell neoplasms that show features intermediate between DLBCL and classical Hodgkin lymphoma, or between DLBCL and BL.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Antigens, CD20 / immunology. Antigens, CD5 / immunology. Child. Diagnosis, Differential. Humans. Immunophenotyping. World Health Organization

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577170.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD5
  • [Number-of-references] 162
  •  go-up   go-down


22. Hinchman KF, Wu JJ, Soden CE Jr, Waldman J, Dyson SW: Multicentric reticulohistiocytosis associated with Burkitt lymphoma and adenocarcinoma. Cutis; 2008 Aug;82(2):113-4
Genetic Alliance. consumer health - Multicentric reticulohistiocytosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric reticulohistiocytosis associated with Burkitt lymphoma and adenocarcinoma.
  • We report a case of MRH in a patient with Burkitt lymphoma and metastatic adenocarcinoma of the gastrointestinal tract.
  • [MeSH-major] Histiocytosis, Non-Langerhans-Cell / diagnosis
  • [MeSH-minor] Adenocarcinoma / complications. Adult. Burkitt Lymphoma / complications. Diagnosis, Differential. Humans. Intestinal Neoplasms / complications. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18792542.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Blinder VS, Chadburn A, Furman RR, Mathew S, Leonard JP: Improving outcomes for patients with Burkitt lymphoma and HIV. AIDS Patient Care STDS; 2008 Mar;22(3):175-87
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving outcomes for patients with Burkitt lymphoma and HIV.
  • Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy that occurs with increased frequency among patients infected with HIV.
  • However, the advent of highly active antiretroviral therapy (HAART) and the mounting evidence that less intensive lymphoma regimens are ineffective in BL have led investigators to treat HIV-positive patients with the same chemotherapy now established as the standard of care for immunocompetent patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Burkitt Lymphoma. Lymphoma, AIDS-Related / physiopathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols. Clinical Trials as Topic. Cyclophosphamide. Doxorubicin. Female. Humans. Immunotherapy. Male. Prednisone. Rituximab. Treatment Outcome. Vincristine

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290753.001).
  • [ISSN] 1557-7449
  • [Journal-full-title] AIDS patient care and STDs
  • [ISO-abbreviation] AIDS Patient Care STDS
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 46
  •  go-up   go-down


24. Queiroga EM, Gualco G, Weiss LM, Dittmer DP, Araujo I, Klumb CE, Harrington WJ Jr, Bacchi CE: Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features. Am J Clin Pathol; 2008 Dec;130(6):946-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features.
  • Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma with a consistent MYC translocation.
  • This is a large-scale study of BL in Brazil, including 234 patients from 5 geographic regions that are widely disparate socioeconomically, including pediatric (61.1%) and adult (37.6%) populations.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1992 Aug 1;52(15):4273-6 [1638540.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]
  • [Cites] Leukemia. 1992 Sep;6(9):875-8 [1325581.001]
  • [Cites] Blood. 1993 Jul 15;82(2):619-24 [8392401.001]
  • [Cites] Am J Clin Pathol. 1994 Jun;101(6):773-82 [8209868.001]
  • [Cites] Br J Haematol. 1995 Jan;89(1):55-60 [7833277.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):17-23 [8546204.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):230-7 [8607450.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Lancet. 1964 Mar 28;1(7335):702-3 [14107961.001]
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2781-7 [15571961.001]
  • [Cites] Blood. 2005 Jul 1;106(1):235-40 [15790788.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):237-42 [16082248.001]
  • [Cites] Nature. 2005 Aug 11;436(7052):807-11 [16094360.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1599-607 [16249378.001]
  • [Cites] Rev Soc Bras Med Trop. 2006 Jan-Feb;39(1):27-31 [16501762.001]
  • [Cites] Oncologist. 2006 Apr;11(4):375-83 [16614233.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):300-4 [17264676.001]
  • [Cites] Int J Lab Hematol. 2007 Aug;29(4):229-60 [17617076.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Am J Clin Pathol. 2007 Oct;128(4):558-64 [17875505.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:277-84 [18024641.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1436-42 [18316607.001]
  • [Cites] Haematologica. 2008 May;93(5):780-3 [18367488.001]
  • [Cites] Hum Pathol. 2008 Oct;39(10):1505-10 [18620733.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1729-34 [11681414.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] J Pathol. 2002 Dec;198(4):417-27 [12434410.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] J Virol. 2004 Feb;78(4):1893-902 [14747554.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):10-8 [15034863.001]
  • [Cites] Pediatr Blood Cancer. 2004 Aug;43(2):115-9 [15236276.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2004;99(5 Suppl 1):13-9 [15486629.001]
  • [Cites] Cancer. 1971 Jul;28(1):89-98 [4938894.001]
  • [Cites] Science. 1983 Nov 18;222(4625):765-71 [6356357.001]
  • [Cites] J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62 [2824665.001]
  • [Cites] Curr Top Microbiol Immunol. 1988;141:128-37 [2850892.001]
  • [Cites] Blood. 1991 Apr 1;77(7):1516-26 [1849033.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5413-7 [2052620.001]
  • [Cites] Blood. 1991 Dec 1;78(11):3004-11 [1659471.001]
  • [Cites] J Pathol. 1992 Mar;166(3):235-41 [1381424.001]
  • (PMID = 19019773.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / D43 TW000017; United States / NCI NIH HHS / CA / 5R01 CA082274; United States / NCI NIH HHS / CA / R01 CA163217; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / R01 CA112217; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / 5R01 CA121935; United States / NCI NIH HHS / CA / R01 CA121935; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NCI NIH HHS / CA / 5R01 CA112217
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS191353; NLM/ PMC2866005
  •  go-up   go-down


25. Onnis A, De Falco G, Antonicelli G, Onorati M, Bellan C, Sherman O, Sayed S, Leoncini L: Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS One; 2010;5(9)
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.
  • BACKGROUND: Burkitt lymphoma (BL) is an aggressive B-cell lymphoma, with a characteristic clinical presentation, morphology and immunophenotype.
  • Deregulation of hsa-miR-9* may therefore be useful as a diagnostic tool, suggesting it as a promising novel candidate for tumor cell marker.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Regulation, Neoplastic. MicroRNAs / genetics. Proto-Oncogene Proteins c-myc / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Child. Child, Preschool. DNA Methylation. E2F1 Transcription Factor / genetics. E2F1 Transcription Factor / metabolism. Female. Humans. Male. Middle Aged. Translocation, Genetic. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2008 Jan;214(1):17-24 [17948228.001]
  • [Cites] Am J Clin Pathol. 2007 Dec;128(6):981-91 [18024324.001]
  • [Cites] Cell Cycle. 2008 Sep 1;7(17):2643-6 [18719391.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Hum Pathol. 2009 Sep;40(9):1252-61 [19368954.001]
  • [Cites] Nat Rev Genet. 2009 Oct;10(10):704-14 [19763153.001]
  • [Cites] Breast Cancer Res Treat. 2009 Nov;118(1):185-96 [18777135.001]
  • [Cites] Int J Cancer. 2010 Mar 15;126(6):1316-26 [19530237.001]
  • [Cites] Nat Cell Biol. 2010 Mar;12(3):247-56 [20173740.001]
  • [Cites] Oncogene. 2010 Mar 4;29(9):1394-404 [19946337.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1301-7 [17485552.001]
  • [Cites] Bioessays. 2002 Jan;24(1):54-64 [11782950.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] RNA. 2003 Mar;9(3):277-9 [12592000.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):905-14 [12718877.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Cell. 2004 Apr 2;117(1):107-16 [15066286.001]
  • [Cites] Cell. 2004 Apr 2;117(1):117-29 [15066287.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7837-41 [6818551.001]
  • [Cites] Nature. 1997 May 22;387(6631):422-6 [9163430.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6485-7 [16061622.001]
  • [Cites] Mol Cells. 2005 Oct 31;20(2):157-66 [16267388.001]
  • [Cites] RNA. 2006 Feb;12(2):192-7 [16373484.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Retrovirology. 2006;3:68 [17032463.001]
  • [Cites] PLoS Genet. 2007 Aug;3(8):e146 [17784791.001]
  • [Cites] Cell Microbiol. 2007 Dec;9(12):2784-94 [17944962.001]
  • [Cites] RNA Biol. 2007 Nov;4(3):131-7 [18347435.001]
  • (PMID = 20930934.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / MIRN92 microRNA, human; 0 / MicroRNAs; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ PMC2945769
  •  go-up   go-down


26. Gerecitano J, Straus DJ: Treatment of Burkitt lymphoma in adults. Expert Rev Anticancer Ther; 2006 Mar;6(3):373-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Burkitt lymphoma in adults.
  • Since its initial description in 1958, Burkitt lymphoma has become a prototype for our understanding of the pathogenesis and optimal treatment of aggressive lymphomas.
  • Special issues in the treatment of Burkitt lymphoma will also be discussed, including considerations in patients infected with HIV and current views on prophylactic measures and treatment of tumor lysis syndrome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Age Factors. HIV Infections / complications. Humans. Prognosis. Tumor Lysis Syndrome / etiology. Tumor Lysis Syndrome / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503854.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 64
  •  go-up   go-down


27. Zeng W, Lechowicz MJ, Winton E, Cho SM, Galt JR, Halkar R: Spectrum of FDG PET/CT findings in Burkitt lymphoma. Clin Nucl Med; 2009 Jun;34(6):355-8
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of FDG PET/CT findings in Burkitt lymphoma.
  • PURPOSE: F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is known to be a useful diagnostic tool for staging, restaging, and monitoring therapy for lymphoma.
  • The purpose of this retrospective study is to present a spectrum of FDG PET findings at initial presentation of Burkitt lymphoma and subsequent findings after therapy.
  • METHOD AND MATERIALS: We retrospectively reviewed 48 patients with Burkitt lymphoma referred for a total of 160 FDG PET/computed tomography (CT) scans at our institution.
  • We characterized the disease distribution of Burkitt lymphoma in all patients and measured representative FDG activity from initial staging scans.
  • RESULTS: Of the 48 patients diagnosed with Burkitt lymphoma, 25 patients had FDG PET/CT scans for initial staging.
  • All untreated lesions of Burkitt lymphoma were highly FDG avid.
  • CONCLUSION: The American (or sporadic) form of Burkitt lymphoma presented with intense hypermetabolic lesions when untreated.
  • [MeSH-major] Burkitt Lymphoma / radiography. Burkitt Lymphoma / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Child, Preschool. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19487844.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


28. Malani AK, Gupta C, Weigand RT, Gupta V, Rangineni G: Spinal Burkitt's lymphoma in adults. Clin Lymphoma Myeloma; 2006 Jan;6(4):333-6
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal Burkitt's lymphoma in adults.
  • Adult Burkitt's lymphoma is an uncommon disease.
  • Few cases of spinal involvement in adults with sporadic Burkitt's lymphoma are reported in the literature.
  • Histologic examination revealed a primary Burkitt's lymphoma of the spinal cord.
  • We also present a review of the literature for the etiology and clinical features of other spinal lymphomas and Burkitt's lymphoma involving the spine in adults.
  • [MeSH-major] Burkitt Lymphoma / pathology. Epidural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507212.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Suchová K, Obrtlíková P, Binder T, Halaska M, Feldmár P, Spálová I, Sucharová E, Rob L, Trnĕný M: [Burkitt lymphoma in pregnancy--case report]. Ceska Gynekol; 2010 May;75(3):248-51
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Burkitt lymphoma in pregnancy--case report].
  • The data we used focused on non- Hodgkin's lymphomas diagnosed during pregnancy, especially on Burkitt lymphoma.
  • According to the literature the Burkitt lymphoma is potencialy currable disease during pregnancy.

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731306.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


30. Wanschitz J, Dichtl W, Budka H, Löscher WN, Boesch S: Acute motor and sensory axonal neuropathy in Burkitt-like lymphoma. Muscle Nerve; 2006 Oct;34(4):494-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute motor and sensory axonal neuropathy in Burkitt-like lymphoma.
  • Immune-mediated neuropathies associated with non-Hodgkin's lymphoma are rare and can be difficult to delineate from neuropathies of other etiologies.
  • We report the clinical and pathological findings of a 36-year-old patient with fulminant quadriplegic neuropathy, left facial nerve palsy, and Burkitt-like lymphoma.
  • We hypothesize that immune mechanisms triggered by the lymphoma initiated damage to the peripheral nervous system and enhanced its vulnerability to the toxic effects of vincristine.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Burkitt Lymphoma / drug therapy. Peripheral Nervous System Diseases / chemically induced. Vincristine / adverse effects
  • [MeSH-minor] Acute Disease. Adult. Axons / drug effects. Axons / pathology. Diagnosis, Differential. Female. Guillain-Barre Syndrome / chemically induced. Guillain-Barre Syndrome / diagnosis. Humans. Quadriplegia / chemically induced

  • Genetic Alliance. consumer health - Motor neuropathy.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16671108.001).
  • [ISSN] 0148-639X
  • [Journal-full-title] Muscle & nerve
  • [ISO-abbreviation] Muscle Nerve
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


31. Haralambieva E, Boerma EJ, van Imhoff GW, Rosati S, Schuuring E, Müller-Hermelink HK, Kluin PM, Ott G: Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol; 2005 Aug;29(8):1086-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma.
  • A prompt distinction of Burkitt lymphoma (BL) versus diffuse large B cell lymphomas (DLBCL) has important clinical implications; however, this distinction can be difficult.
  • We analyzed 74 adult gray zone and 10 reference pediatric BL using immunohistochemistry (Ki-67, CD10, bcl2, bcl6) and fluorescence in situ hybridization (FISH) for MYC, BCL2, and BCL6 breakpoints.
  • In the adult group, algorithm A resulted in 21 adult BL and 52 DLBCL and algorithm B in 23 BL and 51 "non-Burkitt" lymphomas (nBL); 9 cases (12%) contained two different translocations and were categorized as nBL in algorithm B.
  • [MeSH-major] Burkitt Lymphoma / genetics. Lymphoma / genetics. Lymphoma / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Algorithms. Biomarkers, Tumor / analysis. Child. Child, Preschool. DNA-Binding Proteins / analysis. Female. Humans. Immunohistochemistry. Immunophenotyping. Ki-67 Antigen / analysis. Male. Middle Aged. Neprilysin / analysis. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006805.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


32. Balasubramaniam R, Goradia A, Turner LN, Stoopler ET, Alawi F, Frank DM, Greenberg MS: Burkitt lymphoma of the oral cavity: an atypical presentation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Feb;107(2):240-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma of the oral cavity: an atypical presentation.
  • Burkitt lymphoma (BL) is an aggressive form of non-Hodgkin B-cell lymphoma with 3 variants: endemic, sporadic, and immunodeficiency-associated types.
  • An incisional biopsy revealed a diffuse proliferation of intermediate- to large-sized lymphocytes with multiple small peripheral nucleoli, scant cytoplasm, and nuclear pleomorphism.
  • [MeSH-major] Burkitt Lymphoma / pathology. Gingival Neoplasms / pathology. Mandibular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Infusions, Intralesional. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138642.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


33. Xie X, Xu W, Qiu H: [The cytogenetic features of Burkitt leukemia]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr;25(2):214-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The cytogenetic features of Burkitt leukemia].
  • OBJECTIVE: To evaluate the incidence of chromosomal abnormalities in Burkitt leukemia (BL).
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosome Aberrations
  • [MeSH-minor] Adolescent. Adult. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393250.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


34. Sağlam M, Yilmaz MI, Mas MR, Taşçi I, Ors F, Sönmez A, Deveci S: A case of pancreatic Burkitt lymphoma: radiological findings. Diagn Interv Radiol; 2009 Mar;15(1):39-42
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pancreatic Burkitt lymphoma: radiological findings.
  • Burkitt lymphoma predominantly involving the pancreas is very rare.
  • We here report ultrasonography, computed tomography and magnetic resonance imaging findings of primary pancreatic Burkitt lymphoma in a case with unusual radiological presentation.
  • [MeSH-major] Burkitt Lymphoma / radiography. Pancreatic Neoplasms / radiography
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263373.001).
  • [ISSN] 1305-3612
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


35. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer; 2006 Apr 1;106(7):1569-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
  • BACKGROUND: Adult Burkitt-type lymphoma (BL) and acute lymphoblastic leukemia (B-ALL) are rare entities composing 1% to 5% of non-Hodgkin lymphomas NHL) or ALL.
  • CONCLUSIONS: The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


36. Onciu M, Schlette E, Zhou Y, Raimondi SC, Giles FJ, Kantarjian HM, Medeiros LJ, Ribeiro RC, Pui CH, Sandlund JT: Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer; 2006 Sep 1;107(5):1084-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma.
  • BACKGROUND: Karyotypic abnormalities in sporadic Burkitt lymphoma (BL) have been described extensively.
  • However, to the authors' knowledge, very limited studies have focused on the secondary chromosomal abnormalities in pediatric BL as compared with those of adult BL and on their prognostic impact.
  • METHODS: A retrospective analysis was performed in all pediatric and adult patients at 2 institutions, with a morphologic diagnosis of BL, pretherapy tumor karyotype available, and t(8;14), t(8;22), or t(2;8) present.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosome Aberrations
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16862570.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. van Imhoff GW, van der Holt B, MacKenzie MA, Ossenkoppele GJ, Wijermans PW, Kramer MH, van 't Veer MB, Schouten HC, van Marwijk Kooy M, van Oers MH, Raemaekers JM, Sonneveld P, Meulendijks LA, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON): Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia; 2005 Jun;19(6):945-52
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
  • The feasibility and efficacy of up-front high-dose sequential chemotherapy followed by autologous stem cell transplantation (ASCT) in previously untreated adults (median age 33 years; range 15-64) with Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or lymphoblastic lymphoma (LyLy), both without central nervous system or extensive bone marrow involvement was investigated in a multicenter phase II study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800666.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone
  •  go-up   go-down


38. Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW: Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma; 2009 Aug;9(4):307-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.
  • Burkitt lymphoma is a highly curable disorder when treated with modern intensive chemotherapy regimens.
  • The majority of adult patients with Burkitt lymphoma in the United States are over age 40 years.
  • We therefore obtained and analyzed primary data from 14 Burkitt lymphoma treatment series and confirmed that older patients (age > 40 years) are underrepresented in the literature.
  • We conclude that (1) modern intensive chemotherapy regimens should remain the standard of care for patients > age 40 with Burkitt lymphoma;.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Oncology (Williston Park). 2008 Nov 30;22(13):1508-17 [19133605.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2232-3 [12805320.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1438-48 [15042678.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1072-8 [15205201.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] Br J Haematol. 1989 Mar;71(3):371-6 [2930722.001]
  • [Cites] Ann Hematol. 1992 Nov;65(5):201-5 [1457577.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Feb;5(2):118-47 [17335683.001]
  • [Cites] Cancer Invest. 2007 Mar;25(2):87-93 [17453819.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5316-9 [18854560.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:341-8 [19074108.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • (PMID = 19717381.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / T32 HL007152-31; United States / NCI NIH HHS / CA / CA031946-27; United States / NHLBI NIH HHS / HL / HL007152-33; United States / NCI NIH HHS / CA / U10 CA031946; United States / NHLBI NIH HHS / HL / HL007152-32; United States / NCI NIH HHS / CA / U10 CA031946-28; United States / NHLBI NIH HHS / HL / T32 HL007152; United States / NCI NIH HHS / CA / CA031946-28; United States / NHLBI NIH HHS / HL / HL007152-31; United States / NHLBI NIH HHS / HL / T32 HL007152-33; United States / NHLBI NIH HHS / HL / HL007152; United States / NHLBI NIH HHS / HL / T32 HL007152-32; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / U10 CA031946-27
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS207721; NLM/ PMC2909640
  •  go-up   go-down


39. Gupta H, Davidoff AM, Pui CH, Shochat SJ, Sandlund JT: Clinical implications and surgical management of intussusception in pediatric patients with Burkitt lymphoma. J Pediatr Surg; 2007 Jun;42(6):998-1001; discussion 1001
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications and surgical management of intussusception in pediatric patients with Burkitt lymphoma.
  • BACKGROUND/PURPOSE: Intussusception as a presenting feature of Burkitt lymphoma may be associated with early stage disease, which is curable with less intensive therapy.
  • We determined the incidence, presentation, stage, and outcome of children with Burkitt lymphoma presenting with intussusception.
  • METHODS: The medical records of patients with Burkitt lymphoma treated at our hospital from 1962 to 2005 were reviewed, and the patients presenting with intussusception were then further analyzed.
  • RESULTS: Of 189 patients with primary abdominal Burkitt lymphoma, 33 (17.5%) presented with intussusception.
  • Twenty-three (70%) of these 33 patients as compared with 10 of the other 156 patients with abdominal lymphoma could have complete resection of their tumor (P < .0001) and hence had low stage disease (stage II).
  • CONCLUSION: Pediatric patients with Burkitt lymphoma presenting with intussusception often have completely resectable disease and are older than general pediatric patients with intussusception.
  • [MeSH-major] Abdominal Neoplasms / complications. Burkitt Lymphoma / complications. Intussusception / surgery
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Adult. Age Factors. Child. Child, Preschool. Combined Modality Therapy. Early Diagnosis. Female. Humans. Incidence. Male. Nausea / etiology. Neoplasm Staging. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / mortality. Remission Induction. Treatment Outcome. Vomiting / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560209.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Just PA, Fieschi C, Baillet G, Galicier L, Oksenhendler E, Moretti JL: 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDS; 2008 Sep;22(9):695-700
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma.
  • This study aims to describe 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) findings in patients with AIDS-related Burkitt lymphoma, at various times of treatment, and to define its utility for a better patient management.
  • We retrospectively studied 13 consecutive HIV-positive patients with Burkitt lymphoma who underwent one or more PET/CT.
  • Lymph node involvement, which is known to be uncommon in endemic or sporadic Burkitt lymphoma, was present in 54% of patients.
  • Additionally, in 3 patients, Burkitt lymphoma was predominantly located in parotid lymph nodes, which is also an unusual finding.
  • We recommend PET/CT for accurate initial staging of patients with AIDS-related Burkitt lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Fluorodeoxyglucose F18. Lymphoma, AIDS-Related / diagnosis. Radiopharmaceuticals
  • [MeSH-minor] Adult. Female. Humans. Lymph Nodes / radionuclide imaging. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793085.001).
  • [ISSN] 1557-7449
  • [Journal-full-title] AIDS patient care and STDs
  • [ISO-abbreviation] AIDS Patient Care STDS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


41. Bellan C, Stefano L, Giulia de F, Rogena EA, Lorenzo L: Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. Hematol Oncol; 2010 Jun;28(2):53-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
  • Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tumours as an 'aggressive B-cell non-Hodgkin's lymphoma', characterized by a high degree of proliferation of the malignant cells and deregulation of the c-MYC gene.
  • The main diagnostic challenge in BL is to distinguish it from diffuse large B-cell lymphoma (DLBCL).
  • This review summarizes the current practical approach, including the use of a large panel of antibodies, and cytogenetic and molecular diagnostic techniques, to distinguish between BL, DLBCL and the provisional category of 'B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma', now listed in the updated WHO classification.
  • [MeSH-major] B-Lymphocytes / pathology. Burkitt Lymphoma / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Biopsy. Child. Diagnosis, Differential. Disease Management. Gene Expression Profiling. Genes, Immunoglobulin. Genes, bcl-2. Genes, myc. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Translocation, Genetic

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19844983.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 17
  •  go-up   go-down


42. Magrath IT: Treatment of Burkitt lymphoma in children and adults: Lessons from Africa. Curr Hematol Malig Rep; 2006 Dec;1(4):230-40
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Burkitt lymphoma in children and adults: Lessons from Africa.
  • Modern chemotherapy for childhood Burkitt lymphoma has its origins in Africa, where treatment evolved from one or two doses of single agents, which were curative in some patients, to combinations of non-cross-resistant drugs.
  • Therapy regimens for adults with Burkitt lymphoma have been developed by modifying second-generation pediatric protocols, and few investigators have used the third-generation pediatric regimens that include higher doses of methotrexate and additional agents.
  • The weight of evidence strongly suggests that high-dose therapy with stem cell rescue in first remission cannot substitute for intensive therapy from the outset.
  • Because childhood diffuse large-B-cell leukemia (DLBCL) responds equally well to therapy for Burkitt lymphoma, more intensive therapy and intensive support might also give better results in at least a subset of adults with advanced DLBCL-perhaps defined on the basis of limited molecular profiling, which has provided new information about the categories of aggressive B-cell lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Age Factors. Anthracyclines / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antimetabolites, Antineoplastic / administration & dosage. Central Nervous System / pathology. Child. Diagnosis, Differential. Drug Therapy / trends. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Methotrexate / administration & dosage. Randomized Controlled Trials as Topic / statistics & numerical data. Rituximab. Salvage Therapy. Treatment Outcome. Uganda / epidemiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1967 May;20(5):756-9 [6024288.001]
  • [Cites] Br Med J. 1967 Nov 11;4(5575):323-7 [6053614.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2783-8 [12065554.001]
  • [Cites] N Engl J Med. 1977 Jul 14;297(2):75-80 [865579.001]
  • [Cites] Onkologie. 1986 Apr;9(2):126-30 [3520421.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] Med Pediatr Oncol. 2001 Nov;37(5):432-41 [11745871.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1507-15 [6244085.001]
  • [Cites] Blood. 1984 May;63(5):1102-11 [6546890.001]
  • [Cites] Cancer. 1978 Mar;41(3):1059-63 [638947.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):538-9 [14998863.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] Pediatr Hematol Oncol. 1986;3(1):11-8 [3153214.001]
  • [Cites] Leukemia. 2005 Apr;19(4):659-63 [15716988.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 1:77-81 [9187436.001]
  • [Cites] Int J Cancer. 1972 Sep 15;10(2):254-61 [4574467.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):240-8 [8558204.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):133-8 [1985162.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1973-82 [1941056.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1196-205 [12973843.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):115-21 [15350300.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):353-8 [14735176.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • [Cites] Ann Oncol. 1995 May;6(5):445-51 [7545428.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4244 [14623773.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1928-35 [16284057.001]
  • [Cites] Med Oncol. 2005;22(3):257-67 [16110137.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 4):33-9; discussion 45-8 [9578060.001]
  • [Cites] Blood. 1988 Aug;72(2):792-5 [3401598.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):285-91 [11900213.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Summer;13(2):222-46 [2069232.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3713-20 [11389007.001]
  • [Cites] Leuk Res. 1980;4(1):33-59 [6968008.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Int J Cancer. 1976 Apr 15;17(4):436-40 [776840.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4014-22 [11600602.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] JAMA. 1972 Nov 27;222(9):1166 [4678054.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Br Med J. 1971 Aug 26;3(5773):508-12 [5109411.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):211-9 [1703226.001]
  • [Cites] Am J Med. 1975 Mar;58(3):314-21 [1115074.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1732-9 [3491184.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):661-5 [2313335.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):445-9 [15653703.001]
  • [Cites] Int J Cancer. 1980 Sep 15;26(3):261-6 [7287207.001]
  • [Cites] Acta Radiol Ther Phys Biol. 1977 Jun;16(3):225-31 [906892.001]
  • [Cites] Br J Haematol. 2004 Sep;126(6):815-20 [15352985.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Hematol Oncol. 1991 Jul-Oct;9(4-5):267-74 [1743629.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2465-72 [8823324.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1438-48 [15042678.001]
  • [Cites] Cancer. 1976 Sep;38(3):1043-51 [782684.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):559-65 [6338381.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Cancer. 1970 Aug;26(2):474-84 [5468593.001]
  • [Cites] Cancer Res. 1967 Dec;27(12):2578-615 [6082297.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Haematol Blood Transfus. 1977;20:297-305 [580252.001]
  • [Cites] Ann Hematol. 1992 Nov;65(5):201-5 [1457577.001]
  • (PMID = 20425318.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites, Antineoplastic; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 78
  •  go-up   go-down


43. Leucci E, Cocco M, Onnis A, De Falco G, van Cleef P, Bellan C, van Rijk A, Nyagol J, Byakika B, Lazzi S, Tosi P, van Krieken H, Leoncini L: MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol; 2008 Dec;216(4):440-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.
  • The molecular feature of Burkitt lymphoma (BL) is the translocation that places c-Myc under the control of immunoglobulin gene regulatory elements.
  • In addition, during the EUROFISH project, aiming at the standardization of FISH procedures in lymphoma diagnosis, we found that five cases out of 35 classic endemic BLs were negative for MYC translocations by using a split-signal as well as a dual-fusion probe.
  • Here we investigated the expression pattern of miRNAs predicted to target c-Myc, in BL cases, to clarify whether alternative pathogenetic mechanisms may be responsible for lymphomagenesis in cases lacking the MYC translocation. miRNAs are a class of small RNAs that are able to regulate gene expression at the post-transcriptional level.
  • They have also been shown to control cell growth, differentiation, and apoptosis, suggesting that these molecules could act as tumour suppressors or oncogenes.
  • These results indicate for the first time that hsa-mir-34b may influence c-Myc expression in Burkitt lymphoma as the more common aberrant control exercised by the immunoglobulin enhancer locus.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Regulation, Neoplastic. MicroRNAs / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Gene Expression. Genes, Immunoglobulin. Genes, myc. Humans. In Situ Hybridization, Fluorescence / methods. Male. Reverse Transcriptase Polymerase Chain Reaction / methods. Translocation, Genetic. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18802929.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN34 microRNA, human; 0 / MicroRNAs; 0 / mirnlet7 microRNA, human
  •  go-up   go-down


44. Teitell MA, Lones MA, Perkins SL, Sanger WG, Cairo MS, Said JW: TCL1 expression and Epstein-Barr virus status in pediatric Burkitt lymphoma. Am J Clin Pathol; 2005 Oct;124(4):569-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TCL1 expression and Epstein-Barr virus status in pediatric Burkitt lymphoma.
  • Elevated T-cell leukemia-1 (TCL1) oncoprotein expression might promote human Burkitt lymphoma (BL) because increased TCL1 causes Burkitt-like lymphomas in TCL1 transgenic mice.
  • Epstein-Barr virus (EBV) infection has been implicated as a cause of increased TCL1 expression in multiple BL cell lines, suggesting a critical connection between EBV and TCL1-induced BL.
  • However, persistent EBV is not essential for increased TCL1 expression, although elevated TCL1 and c-MYC coexpression might cooperate in the development of most pediatric and adult BL cases.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Herpesvirus 4, Human / isolation & purification. Lymphoid Tissue / metabolism. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Child. Child, Preschool. Chromosome Banding. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Karyotyping. Male. RNA, Viral / analysis. RNA-Binding Proteins / metabolism. Ribosomal Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146820.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107300; United States / NCI NIH HHS / CA / R01 CA90571
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / RNA, Viral; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / TCL1A protein, human; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


45. Gormley RP, Madan R, Dulau AE, Xu D, Tamas EF, Bhattacharyya PK, LeValley A, Xue X, Kumar P, Sparano J, Ramesh KH, Pulijaal V, Cannizzaro L, Walsh D, Ioachim HL, Ratech H: Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases. Am J Clin Pathol; 2005 Nov;124(5):790-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases.
  • Morphologic features of Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) overlap.
  • We tested a panel of 8 germinal center (GC) and activated B-cell (ABC) markers for their ability to separate BL and DLBCL.
  • [MeSH-major] B-Lymphocytes / immunology. Burkitt Lymphoma / pathology. Germinal Center / immunology. Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymphocyte Activation. Male. Middle Aged. Retrospective Studies


46. Kluiver J, Haralambieva E, de Jong D, Blokzijl T, Jacobs S, Kroesen BJ, Poppema S, van den Berg A: Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer; 2006 Feb;45(2):147-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma.
  • We previously demonstrated high expression of primary-microRNA BIC (pri-miR-155) in Hodgkin lymphoma (HL) and lack of expression in most non-Hodgkin lymphoma subtypes including some Burkitt lymphoma (BL) cases.
  • In this study, we extended our series of BL cases and cell lines to examine expression of BIC using RNA in situ hybridization (ISH) and quantitative RT-PCR (qRT-PCR) and of miR-155 using Northern blotting.
  • EBV-negative and EBV latency type I BL cell lines also showed very low BIC and miR-155 expression levels as compared to HL cell lines.
  • Higher levels of BIC and miR-155 were detected in in vitro transformed lymphoblastoid EBV latency type III BL cell lines.
  • Expression of BIC and miR-155 in 3 latency type III EBV-positive BL cell lines and in all primary PTLD cases suggests a possible role for EBV latency type III specific proteins in the induction of BIC expression.
  • [MeSH-major] Burkitt Lymphoma / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adolescent. Adult. Blotting, Northern. Cell Line, Tumor. Child. Child, Preschool. Genes, myc. Humans. Immunohistochemistry. In Situ Hybridization. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235244.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


47. Nomura Y, Yoshida S, Karube K, Takeshita M, Hirose S, Nakamura S, Yoshino T, Kikuchi M, Ohshima K: Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma. Cancer Sci; 2008 Aug;99(8):1564-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma.
  • Burkitt's lymphoma and atypical Burkitt/Burkitt-like lymphoma (BL/BLL) are considered highly aggressive B-cell lymphomas with a rapid proliferative rate and high rate of apoptosis.
  • The aim of the present study was to confirm whether apoptotic and cell proliferative factors affect BL/BLL clinical outcomes.
  • [MeSH-major] Biomarkers, Tumor. Burkitt Lymphoma / genetics. Caspase 3 / metabolism. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / genetics. Cell Proliferation. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gene Expression. Genes, bcl-2 / genetics. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754867.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.22.- / Caspase 3; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


48. Leucci E, Onnis A, Cocco M, De Falco G, Imperatore F, Giuseppina A, Costanzo V, Cerino G, Mannucci S, Cantisani R, Nyagol J, Mwanda W, Iriso R, Owang M, Schurfeld K, Bellan C, Lazzi S, Leoncini L: B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. Int J Cancer; 2010 Mar 15;126(6):1316-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression.
  • Endemic, sporadic and HIV-associated Burkitt lymphoma (BL) all have a B-cell phenotype and a MYC translocation, but a variable association with the Epstein-Barr virus (EBV).
  • The appearance of a germinal center phenotype in EBV-positive cells might thus derive from a block in B-cell differentiation.
  • Here, we investigated the expression of specific miRNAs predicted to be involved in B-cell differentiation and found that hsa-miR-127 is differentially expressed between EBV-positive and EBV-negative BLs.
  • In addition, we found evidence that hsa-miR-127 is involved in B-cell differentiation process through posttranscriptional regulation of BLIMP1 and XBP1.
  • The overexpression of this miRNA may thus represent a key event in the lymphomagenesis of EBV positive BL, by blocking the B-cell differentiation process.
  • [MeSH-major] B-Lymphocytes / metabolism. Burkitt Lymphoma / genetics. Cell Differentiation. MicroRNAs / genetics. RNA Processing, Post-Transcriptional
  • [MeSH-minor] Adolescent. Adult. Blotting, Western. Cell Line, Tumor. Child. Child, Preschool. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Herpesvirus 4, Human / growth & development. Humans. Male. Middle Aged. Repressor Proteins / genetics. Repressor Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / genetics. Transcription Factors / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530237.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MIRN127 microRNA, human; 0 / MicroRNAs; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / regulatory factor X transcription factors; 138415-26-6 / PRDM1 protein, human
  •  go-up   go-down


49. Gottwald L, Korczyński J, Góra E, Pasz-Walczak G, Jesionek-Kupnicka D, Bieńkiewicz A: [Abdominal Burkitt lymphoma mimicking the ovarian cancer. Case report and review of the literature]. Ginekol Pol; 2008 Feb;79(2):141-5
Genetic Alliance. consumer health - Ovarian cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abdominal Burkitt lymphoma mimicking the ovarian cancer. Case report and review of the literature].
  • Primary Burkitt lymphoma is a lymphoblastic B-cell malignant tumor with very aggressive course.
  • CASE: We report the case of 27-year-old woman treated for abdominal Burkitt lymphoma.
  • Pathologic examination has revealed an abdominal Burkitt lymphoma.
  • CONCLUSIONS: The presence of primary abdominal Burkitt lymphoma may include clinical and laboratory findings suggesting the presence of ovarian cancer.
  • Chemotherapy appears to be an essential therapeutic management for all forms of Burkitt lymphoma.
  • Clinically advanced Burkitt lymphoma may be successfully managed with chemotherapy.
  • [MeSH-major] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Burkitt Lymphoma / pathology. Burkitt Lymphoma / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / blood. Diagnosis, Differential. Female. Humans. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovariectomy / methods. Pelvic Pain / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510095.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Number-of-references] 18
  •  go-up   go-down


50. Kujawski LA, Longo WL, Williams EC, Turman NJ, Brandt N, Mosher DF, Eickhoff JC, Kahl BS: A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas. Cancer Invest; 2007 Mar;25(2):87-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
  • Burkitt lymphoma (BL) and Burkitt-like lymphomas (BLL) are clinically and biologically aggressive B-cell malignancies.
  • Brief-duration, high intensity multidrug regimens with central nervous system (CNS) prophylaxis have proven to be effective, with published series of adult patients documenting complete response (CR) rates of 80 to 100 percent and 2-year event-free survival (EFS) rates ranging from 60 to 90 percent.
  • Based upon the known sensitivity of BL to cyclophosphamide and favorable results reported from the Dana Farber Cancer Center using high-dose CHOP in diffuse aggressive lymphomas, we tested a regimen designed to maximize the administered dose of cyclophosphamide while eliminating other agents commonly used in BL protocols.
  • Eleven patients with Burkitt or Burkitt-like lymphoma were treated with 4 cycles of a 5-drug regimen, called high-dose CHOP, which contains a cyclophosphamide dose of 4 gm/m2 with each cycle.
  • Utilization of high dose cyclophosphamide may eliminate the need for several other agents in Burkitt lymphoma regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Cyclophosphamide / administration & dosage. Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Survival. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453819.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


51. Mbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS: Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005. Int J Cancer; 2010 Apr 1;126(7):1732-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005.
  • Burkitt lymphoma (BL) is a unique B-cell non-Hodgkin lymphoma with 3 established clinical-epidemiological variants: endemic, sporadic and AIDS-related BL.
  • Male-to-female incidence rate ratios did not differ by race, but were 4.2 for pediatric (0-19 years), 4.1 for adult (20-59 years) and 2.0 for geriatric (> or = 60 years) BL.
  • [MeSH-major] Burkitt Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. SEER Program. Survival Rate. Time Factors. United States / epidemiology. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 UICC.
  • [Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]
  • [Cites] Biometrics. 1995 Sep;51(3):874-87 [7548706.001]
  • [Cites] Am J Epidemiol. 1996 Jan 1;143(1):85-91 [8533751.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1124 [10025990.001]
  • [Cites] Blood. 1999 Jan 15;93(2):758 [10215347.001]
  • [Cites] Cancer. 1957 Sep-Oct;10(5):1045-54 [13472655.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Ann Intern Med. 1969 Apr;70(4):817-32 [4306129.001]
  • [Cites] Br J Prev Soc Med. 1971 Nov;25(4):242-4 [5160433.001]
  • [Cites] Nature. 1972 May 5;237(5349):33-4 [4113130.001]
  • [Cites] Eur J Cancer. 1972 Jun;8(3):305-8 [4677829.001]
  • [Cites] N Engl J Med. 1981 Sep 24;305(13):735-45 [7022215.001]
  • [Cites] Lancet. 1982 Sep 18;2(8299):631-3 [6125777.001]
  • [Cites] Biometrics. 1983 Jun;39(2):311-24 [6626659.001]
  • [Cites] Stat Med. 1987 Jun;6(4):449-67 [3629047.001]
  • [Cites] Stat Med. 1987 Jun;6(4):469-81 [3629048.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Br J Cancer. 1963 Mar;17:50-5 [14001942.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Nat Rev Microbiol. 2008 Dec;6(12):913-24 [19008891.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:341-8 [19074108.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 17;100(24):1804-14 [19066264.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):366-70 [19434731.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2256-61 [19622723.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Jun 2;55(21):589-92 [16741494.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] MMWR Suppl. 1987 Dec 25;36(7):1S-20S [2826984.001]
  • [Cites] Annu Rev Public Health. 1991;12:425-57 [2049144.001]
  • [Cites] Am J Epidemiol. 1987 Oct;126(4):578-86 [3631049.001]
  • (PMID = 19810101.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010176-07; United States / Intramural NIH HHS / / ZIA CP010176-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS146203; NLM/ PMC2818154
  •  go-up   go-down


52. Chuang SS, Huang WT, Hsieh PP, Jung YC, Ye H, Du MQ, Lu CL, Cho CY, Hsiao SC, Hsu YH, Lin KJ: Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features. Histopathology; 2008 Mar;52(4):427-35
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features.
  • AIMS: To characterize the clinicopathological features of sporadic Burkitt lymphoma (BL).
  • METHODS AND RESULTS: A retrospective study of 17 paediatric and 14 adult BLs with history and histopathology review, immunohistochemistry, Epstein-Barr virus (EBV) in situ hybridization (EBER) and fluorescence in situ hybridization.
  • There was no statistically significant difference in gender, frequency of central nervous system (CNS) involvement and leukaemic change at presentation, or frequency of CD10+/Bcl-2-/Bcl-6+ (88% versus 86%), Ki67 labelling index, EBER (24% versus 21%), or C-MYC translocation (100% versus 92%) between paediatric and adult tumours.
  • Correct pretreatment diagnoses were made in 13/17 (76%) paediatric and in 9/14 (64%) adult tumours.
  • Twenty-eight patients received chemotherapy including 13/16 (81%) paediatric and 3/12 (25%) adult patients with appropriate regimens; 16 (57%) received CNS prophylaxis.
  • CONCLUSIONS: Sporadic paediatric and adult BLs were phenotypically and genotypically similar.
  • The poor outcome in adult patients might be related to incorrect diagnosis and inappropriate treatment.
  • [MeSH-major] Burkitt Lymphoma / pathology. Central Nervous System Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Child, Preschool. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / virology. Female. Genotype. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization, Fluorescence. Infant. Male. Middle Aged. Phenotype. RNA, Viral / analysis. RNA-Binding Proteins / analysis. Retrospective Studies. Ribosomal Proteins / analysis. Survival Rate. Taiwan / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315595.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


53. Tanimura A, Adachi Y, Tanda M, Yuasa H, Ishii Y, Katou Y: Primary peripheral B cell lymphoma, Burkitt-like, of the cranial vault. Acta Haematol; 2005;113(4):258-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peripheral B cell lymphoma, Burkitt-like, of the cranial vault.
  • We report an autopsy case of malignant lymphoma of the cranial vault.
  • Autopsy revealed that the tumor was composed of medium-sized cells which were immunoreactive with CD45, CD20, CD79a, and CD10, and a diagnosis of peripheral B cell lymphoma, Burkitt-like, was made.
  • Non-Hodgkin lymphoma originating from the cranial vault is extremely rare; a search of the English literature revealed only 16 previously reported cases.
  • Herein, we review this singular calvarial lymphoma.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Skull / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel
  • (PMID = 15983433.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 20
  •  go-up   go-down


54. Choi MK, Jun HJ, Lee SY, Kim KH, Lim DH, Kim K, Ko YH, Kim WS, Kim SJ: Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. Ann Hematol; 2009 Nov;88(11):1099-106
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
  • Burkitt lymphoma (BL) is a rare subtype of adult non-Hodgkin lymphoma, so studies on the outcome of adult BL, especially in Asian patients, are scarce.
  • We report our results using the LMB protocol on Korean adult BL patients.
  • All of the non-CR patients died, including five PR and one with progressive disease.
  • In conclusion, the LMB protocol was effective for Korean adult BL patients.
  • However, considering the high incidence of treatment-related deaths and the poor outcome of non-CR patients, risk-adapted modification of the induction phase is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Evaluation. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Hematologic Diseases / chemically induced. Hematologic Diseases / epidemiology. Humans. Kaplan-Meier Estimate. Korea / epidemiology. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Sepsis / epidemiology. Sepsis / etiology. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288103.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


55. Yoruk O, Ucuncu H, Gursan N, Aktan B, Sutbeyaz Y, Altas E, Tatar AO: Sinonasal Burkitt lymphoma presenting as a nasal polyposis in a pregnant woman. J Craniofac Surg; 2009 Jul;20(4):1059-60
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal Burkitt lymphoma presenting as a nasal polyposis in a pregnant woman.
  • The incidence of Burkitt lymphoma (BL) during pregnancy is rare.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Nasal Polyps / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Endoscopy. Female. Humans. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19634216.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


56. Cui T, Wang C, He H, Shi G, Hu L: A rare case of ovarian Burkitt lymphoma associated tumor lysis syndrome. Eur J Gynaecol Oncol; 2010;31(2):209-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of ovarian Burkitt lymphoma associated tumor lysis syndrome.
  • A bilateral salpingo-oophorectomy was performed and pathological diagnosis showed Burkitt lymphoma of bilateral ovaries.
  • This is the first report on the post-treatment tumor lysis syndrome with ovarian Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / drug therapy. Cisplatin / adverse effects. Ovarian Neoplasms / drug therapy. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Ovariectomy. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20527243.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


57. Paissan A, Wachs A, Arias M, Abeldaño A, Frider B: [Obstructive jaundice associated Burkitt's lymphoma mimicking pancreatic carcinoma]. Acta Gastroenterol Latinoam; 2007 Dec;37(4):246-9
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Obstructive jaundice associated Burkitt's lymphoma mimicking pancreatic carcinoma].
  • [Transliterated title] Ictericia obstructiva asociada a linfoma de Burkitt en un adulto inmunocompetente.
  • However, in advanced stages of Non-Hodgkin's lymphomas (LNH) the secondary invasion of the pancreas is observed more frequently.
  • The aim is to present a case of an obstructive jaundice as an expression of Burkitt's lymphoma probably due to a diffuse pancreatic infiltration in an adult without immunodeficiency with a rapid response of cholestasis to low dose of hydrocortisone.
  • There are isolated reports of Burkitt's lymphoma cases with associated obstructive jaundice due to pancreatic infiltration or by compression by lymph nodes of the bile ducts, many of them are pediatric cases or immunodepressed HIV patients.
  • We think the interest in this case is the quick response to low doses of corticoids, which avoided the necessity of surgical procedure for the diagnosis of the biliary tree obstruction, allowing a quick implementation of the specific chemotherapeutic treatment of the lymphoma without any surgical or endoscopic procedures to heal the jaundice.
  • [MeSH-major] Burkitt Lymphoma / complications. Jaundice, Obstructive / etiology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Fatal Outcome. Humans. Hydrocortisone / therapeutic use. Male

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254263.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


58. Gobbato PL, Pereira Filho Ade A, de David G, Faria Mde B, de David F, Aleixo PB, Barra MB, Ferreira NP: Primary meningeal Burkitt-type lymphoma presenting as the first clinical manifestation of acquired immunodeficiency syndrome. Arq Neuropsiquiatr; 2006 Jun;64(2B):511-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary meningeal Burkitt-type lymphoma presenting as the first clinical manifestation of acquired immunodeficiency syndrome.
  • The purpose of this study is to report a rare case of primary meningeal high grade Burkitt-type lymphoma presenting as the first clinical manifestation of acquired immunodeficiency syndrome.
  • Pathological studies diagnosed Burkitt-type lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Craniotomy. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917629.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


59. Burmeister T, Schwartz S, Horst HA, Rieder H, Gökbuget N, Hoelzer D, Thiel E: Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. Leukemia; 2005 Aug;19(8):1391-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features.
  • Chromosomal translocations involving the MYC oncogene are a hallmark of Burkitt lymphoma but they are only found in a varying frequency in mature Burkitt-type acute lymphoblastic leukemia (B-ALL).
  • We have investigated samples of 56 sporadic Burkitt leukemia/lymphoma patients for the translocations t(8;14)(q24;q32), t(2;8)(p11;q24) and t(8;22)(q24;q11).
  • [MeSH-major] Burkitt Lymphoma / genetics. Genetic Heterogeneity. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Cytogenetic Analysis. Female. Genes, myc. Humans. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Polymerase Chain Reaction. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Leukemia (2005) 19, 1391-1398.
  • (PMID = 15973450.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


60. McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, Hoering A, Kurtin PJ: Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol; 2005 Dec;29(12):1652-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.
  • Adult, de novo B-cell lymphomas meeting the WHO morphologic criteria for atypical Burkitt/Burkitt-like lymphoma cause diagnostic difficulty for pathologists because the genetic and clinical characteristics of this group of lymphomas have not been clearly defined.
  • Thirty-one such lymphomas, designated as Burkitt-like lymphomas (BLL), were selected based on morphologic features and evaluated for immunophenotype, MYC and BCL2 status, and clinical features.
  • Nine childhood Burkitt lymphomas (BL) and 87 adult, de novo diffuse large B-cell lymphomas (DLBL) were similarly evaluated for comparison.
  • The BL group demonstrated uniform characteristics: all had Burkitt lymphoma morphology, an identical immunophenotype (positive for CD20, CD10, bcl-6, CD43, and p53; negative for CD138, CD23, bcl-2), high MIB-1 positivity, IGH/MYC translocation, no IGH/BCL2 translocation, and all patients were alive at the last follow-up.
  • Burkitt-like morphology alone correlated with decreased survival.
  • We propose that adult B-cell lymphomas with BLL morphology are a phenotypically and genetically heterogeneous group of aggressive lymphomas, biologically distinct from childhood BL.
  • Until biologically accurate subgroups within this morphologically defined group are identified, it is appears that both recognition of BLL morphology and direct evaluation for the presence of MYC fusion to immunoglobulin genes are important for identification of adult patients with poorer prognosis than those with DLBL.
  • [MeSH-major] Burkitt Lymphoma / genetics. Genotype. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Phenotype
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Histocytochemistry. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-myc / analysis. Survival Analysis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327438.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


61. Queiroga EM, Gualco G, Chioato L, Harrington WJ, Araujo I, Weiss LM, Bacchi CE: Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8. Am J Clin Pathol; 2008 Aug;130(2):186-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8.
  • Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma, composed of a monomorphic population of medium-sized B cells with a high proliferation rate and a consistent MYC translocation.
  • Kaposi sarcoma-associated herpesvirus, or human herpesvirus 8 (HHV-8), infects a wide range of normal cells, having a well-established role in the pathogenesis of various neoplasms, including Kaposi sarcoma, primary effusion lymphoma, multicentric Castleman disease (MCD) and MCD-associated plasmablastic lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Aug;19(8):1391-8 [15973450.001]
  • [Cites] J Exp Med. 2005 Aug 15;202(4):479-84 [16103407.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):834-7 [16136049.001]
  • [Cites] J Clin Pathol. 2005 Oct;58(10):1039-45 [16189148.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):123-7 [16330952.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):23-31 [16360412.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Acta Haematol. 2007;117(3):129-31 [17135725.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • [Cites] Haematologica. 2005 Nov;90 Suppl:ECR35 [16266926.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1269-70 [10534180.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]
  • [Cites] Clin Infect Dis. 2002 Feb 15;34(4):559-60 [11797191.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):471-7 [12580962.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Acta Otolaryngol. 2004 Apr;124(3):318-23 [15141762.001]
  • [Cites] J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62 [2824665.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1396-403 [7858270.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):17-23 [8546204.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]
  • [Cites] Arch Dermatol. 1998 Jun;134(6):751 [9645650.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] J Cutan Pathol. 2005 Jan;32(1):21-7 [15660651.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):626-8 [15917415.001]
  • (PMID = 18628086.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / 5R01CA082274; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / U01 CA121947-016821; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / R01 CA121935; United States / NCI NIH HHS / CA / CA121947-016821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS125501; NLM/ PMC2718775
  •  go-up   go-down


62. Schniederjan SD, Li S, Saxe DF, Lechowicz MJ, Lee KL, Terry PD, Mann KP: A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma. Am J Clin Pathol; 2010 May;133(5):718-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma.
  • Rapid and accurate differential diagnosis between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL) is imperative because their treatment differs.
  • Recent studies have characterized several antigens differentially expressed in these 2 types of lymphoma.
  • Twenty-three cases of CD10+ B-cell lymphomas with available cryopreserved samples were identified (13 BL and 10 CD10+ DLBCL).
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antibodies, Neoplasm / immunology. Burkitt Lymphoma / pathology. Flow Cytometry / methods. Lymphoma, Large B-Cell, Diffuse / pathology. Neprilysin / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunophenotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395518.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


63. Salaverria I, Zettl A, Beà S, Hartmann EM, Dave SS, Wright GW, Boerma EJ, Kluin PM, Ott G, Chan WC, Weisenburger DD, Lopez-Guillermo A, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Jaffe ES, Staudt LM, Müller-Hermelink HK, Campo E, Rosenwald A, Leukemia and Lymphoma Molecular Profiling Project (LLMPP): Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica; 2008 Sep;93(9):1327-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma.
  • BACKGROUND: Burkitt's lymphoma is an aggressive B-cell lymphoma characterized by typical morphological, immunophenotypic and molecular features.
  • Gene expression profiling provided a molecular signature of Burkitt's lymphoma, but also demonstrated that a subset of aggressive B-cell lymphomas not fulfilling the current World Health Organization criteria for the diagnosis of Burkitt's lymphoma nonetheless show a molecular signature of Burkitt's lymphoma ('discrepant Burkitt's lymphoma').
  • Given the different treatment of Burkitt's lymphoma and diffuse large B-cell lymphomas we investigated molecular differences within gene expression-defined Burkitt's lymphoma.
  • DESIGN AND METHODS: We studied tumors from 51 Burkitt's lymphoma patients, comprising 26 with classic Burkitt's lymphoma, 17 with atypical Burkitt's lymphoma and 8 with 'discrepant Burkitt's lymphoma', by comparative genomic hybridization and gene expression profiling.
  • RESULTS: Classic and atypical Burkitt's lymphoma (excluding 'discrepant Burkitt's lymphoma'), in adult and pediatric cases do not differ in underlying genomic imbalances or gene expression suggesting that these subgroups are molecularly homogeneous.
  • 'Discrepant Burkitt's lymphoma', however, differ dramatically in the absolute number of alterations from classic/atypical Burkitt's lymphoma and from diffuse large B-cell lymphoma.
  • Moreover, this category includes lymphomas that carry both the t(14;18) and t(8;14) translocations and are clinically characterized by presentation in adult patients and an aggressive course.
  • CONCLUSIONS: Pediatric and adult Burkitt's lymphoma are molecularly homogeneous, whereas 'discrepant Burkitt's lymphoma' differ in underlying genetic and clinical features from typical/atypical Burkitt's lymphoma.
  • 'Discrepant Burkitt's lymphoma' may therefore form a distinct genetic subgroup of aggressive B-cell lymphomas, which show poor response to multi-agent chemotherapy.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human / genetics. Comparative Genomic Hybridization. Gene Expression Regulation, Neoplastic / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698080.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / UO1-CA84967
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


64. Crosswell HE, Bergsagel DJ, Yost R, Lew G: Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma. Pediatr Blood Cancer; 2008 Apr;50(4):883-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
  • Burkitt lymphoma is the most common AIDS-related lymphoma (ARL) in childhood.
  • The major issues in adult and pediatric ARL include identifying the optimal chemotherapy regimen and the concurrent treatment of both rituximab and highly active anti-retroviral therapy (HAART).
  • We present a case of advanced stage Burkitt lymphoma in an 8-year-old female with acquired immunodeficiency syndrome (AIDS), who was successfully treated with a 3 month course of modified CHOP-R (cyclophosphamide, daunorubicin, vincristine, prednisone, and rituximab) and HAART therapy.
  • The combination of rituximab and chemotherapy with HAART therapy may be well-tolerated and effective in HIV/AIDS patients with Burkitt lymphoma.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 17278123.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


65. Nomura S, Ishii K, Shimamoto Y, Yamamoto Y, Kadota E: Burkitt lymphoma of the uterus in a human T lymphotropic virus type-1 carrier. Intern Med; 2006;45(4):215-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma of the uterus in a human T lymphotropic virus type-1 carrier.
  • A 71-year-old Japanese woman who was seropositive for T-lymphotropic virus type-1 (HTLV-1) developed primary Burkitt lymphoma of the uterus.
  • Biopsies from abdominal operation were diagnosed as Burkitt lymphoma.
  • Treatment was started with intensive chemotherapy according to a protocol for Burkitt lymphoma and mature-B cell leukemia.
  • [MeSH-major] Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / virology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Uterine Neoplasms / drug therapy. Uterine Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16543692.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


66. Tauro S, Cochrane L, Lauritzsen GF, Baker L, Delabie J, Roberts C, Mahendra P, Holte H: Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (&lt;50 years): a comparison of two adapted BFM protocols. Am J Hematol; 2010 Apr;85(4):261-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols.
  • The chemotherapy dose-intensity in two adapted German BFM paediatric protocols (BFM 90 and NHL 86) was compared in contemporaneously treated adults <50 years with Burkitt lymphoma and B-cell lymphoma unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (collectively referred to as BL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Prednisolone / administration & dosage. Survival Analysis. Vincristine / administration & dosage. Vindesine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201088.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; RSA8KO39WH / Vindesine; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


67. Nistala SS, Sawalakhe NR, Thiruvengadam NR, Rathi PM: A rare case of primary pancreatic Burkitt lymphoma in a young Indian male. Case report and review of the literature. JOP; 2009;10(6):686-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of primary pancreatic Burkitt lymphoma in a young Indian male. Case report and review of the literature.
  • CONTEXT: Lymphomas of the gastrointestinal system are usually of a non-Hodgkin's type.
  • Primary lymphomas of the pancreas are uncommon and Burkitt lymphoma involving the pancreas is very rare.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Humans. India. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19890195.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 13
  •  go-up   go-down


68. Adeyemi OA, Yeldandi AV, Ison MG: Fatal adenovirus pneumonia in a person with AIDS and Burkitt lymphoma: a case report and review of the literature. AIDS Read; 2008 Apr;18(4):196-8, 201-2, 206-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal adenovirus pneumonia in a person with AIDS and Burkitt lymphoma: a case report and review of the literature.
  • Although adenoviruses are a recognized cause of serious pulmonary and disseminated disease among stem cell transplant recipients, their importance in other immunocompromised patient populations is less clearly documented.
  • We present a case of a person with AIDS who was receiving chemotherapy for Burkitt lymphoma in whom fatal adenovirus pneumonia and adenoviremia developed, and we review the published literature on adenovirus infection in the setting of HIV disease.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Adenoviridae Infections. Burkitt Lymphoma / drug therapy. HIV-1. Lymphoma, AIDS-Related / drug therapy. Pneumonia, Viral
  • [MeSH-minor] Adenoviridae. Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiviral Agents / therapeutic use. Fatal Outcome. Humans. Immunocompromised Host. Male. Withholding Treatment


69. Negahban S, Ahmadi N, Oryan A, Khojasteh HN, Aledavood A, Soleimanpour H, Mohammadianpanah M, Oschlies I, Gesk S, Siebert R, Daneshbod K, Daneshbod Y: Primary bilateral Burkitt lymphoma of the lactating breast: a case report and review of the literature. Mol Diagn Ther; 2010 Aug 01;14(4):243-50
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bilateral Burkitt lymphoma of the lactating breast: a case report and review of the literature.
  • Burkitt lymphoma (BL) is a highly aggressive neoplasm, which frequently affects the ileocecal region in the sporadic form and the jaw in the endemic form; however, the breast is a rare primary site of this tumor.
  • Excisional biopsy of breast masses demonstrated a B-cell lymphoma with a characteristic 'starry sky' pattern highly suggestive of BL.
  • An IGH-MYC gene fusion indicating the presence of a typical Burkitt translocation t(8;14)(q24;q32) in the tumor tissue was detected by fluorescent in situ hybridization.
  • Whether hormonal or antigenic factors trigger Burkitt lymphomagenesis in the lactating breast warrants further investigation.
  • [MeSH-major] Breast Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Lactation. Lactation Disorders / diagnosis
  • [MeSH-minor] Antigens, CD20 / analysis. Cell Proliferation. Diagnosis, Differential. Female. Humans. Ki-67 Antigen / analysis. Neprilysin / analysis. Oncogene Fusion / genetics. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic / genetics. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1173-8 [12916870.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Pediatr Radiol. 1995;25(1):56-7 [7761167.001]
  • [Cites] Cancer. 1987 Dec 15;60(12):3033-41 [3315180.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):397-404 [12764549.001]
  • [Cites] Dtsch Med Wochenschr. 1980 Mar 21;105(12):413-7 [7363786.001]
  • [Cites] Obstet Gynecol. 1980 Oct;56(4):533-6 [7422203.001]
  • [Cites] Am J Dis Child. 1975 Oct;129(10):1219-23 [1190147.001]
  • [Cites] Cancer. 1972 Jun;29(6):1705-12 [4555557.001]
  • [Cites] Acta Haematol. 1980;63(6):330-2 [6774568.001]
  • [Cites] Br J Surg. 1967 Sep;54(9):776-80 [6047810.001]
  • [Cites] Am J Surg Pathol. 1994 Mar;18(3):288-95 [8116797.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1624 [2924269.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):357-64 [10375092.001]
  • [Cites] Jpn J Clin Oncol. 2003 Aug;33(8):399-403 [14523060.001]
  • [Cites] Radiographics. 2007 Oct;27 Suppl 1:S101-24 [18180221.001]
  • [Cites] Am J Hematol. 2006 Feb;81(2):147-8 [16432857.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):253-6 [11703318.001]
  • [Cites] Cancer. 1992 Nov 15;70(10):2451-9 [1423175.001]
  • [Cites] West Afr J Med. 2005 Jul-Sep;24(3):280-2 [16276714.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Conn Med. 1995 Nov;59(11):651-5 [8565509.001]
  • [Cites] Cancer. 1977 May;39(5):2033-40 [322851.001]
  • [Cites] Arch Gynecol Obstet. 2009 Aug;280(2):297-300 [19107501.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1031-4 [1655211.001]
  • [Cites] Clin Imaging. 2006 Jan-Feb;30(1):57-9 [16377487.001]
  • [Cites] Orv Hetil. 1996 Jun 16;137(24):1315-7 [8927329.001]
  • [Cites] Ann Diagn Pathol. 2006 Jun;10(3):144-8 [16730308.001]
  • [Cites] Breast J. 2006 Mar-Apr;12(2):177-8 [16509847.001]
  • [Cites] J Natl Med Assoc. 1994 May;86(5):365-8 [8046764.001]
  • [Cites] Clin Imaging. 2001 Sep-Oct;25(5):309-11 [11682286.001]
  • [Cites] AJR Am J Roentgenol. 2006 Apr;186(4):1029-32 [16554574.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):25-30 [17541937.001]
  • [Cites] J Pediatr Hematol Oncol. 2010 Mar;32(2):e75-8 [20168249.001]
  • [Cites] Arch Gynecol Obstet. 2009 May;279(5):743-6 [18797899.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2602-11 [2249200.001]
  • [Cites] Med Oncol. 2000 Aug;17(3):233-6 [10962537.001]
  • [Cites] JAMA. 1977 Jan 10;237(2):151 [318712.001]
  • [Cites] Gan No Rinsho. 1986 Aug;32(9):1023-7 [3528559.001]
  • [Cites] Ann Pathol. 1998 Jul;18(3):237-8 [9706354.001]
  • [Cites] Diagn Cytopathol. 2002 Jul;27(1):60-2 [12112818.001]
  • [Cites] Pathol Res Pract. 1996 Jan;192(1):37-43 [8685040.001]
  • [Cites] Breast Cancer. 2005;12(3):234-7 [16110296.001]
  • (PMID = 20799767.001).
  • [ISSN] 1179-2000
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-myc; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


70. Choi KA, Lee JE, Kim YG, Kim DJ, Kim K, Ko YH, Oh HY, Kim WS, Huh W: Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. Ann Hematol; 2009 Jul;88(7):639-45
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome.
  • Tumor lysis syndrome (TLS) is a potentially fatal metabolic complication of chemotherapy for Burkitt lymphoma.
  • This retrospective study evaluated the efficacy and safety of continuous venovenous hemofiltration (CVVH) with prephase chemotherapy using the modified LMB-89 regimen in patients with Burkitt lymphoma and leukemia (BL/L) at a high risk of developing TLS from February 1998 to February 2007.
  • Eight patients had Burkitt lymphoma and three had Burkitt leukemia; their median age was 48 years.
  • In conclusion, chemotherapy combined with CVVH might be effective and safe in patients with advanced Burkitt lymphoma and leukemia at a high risk of developing TLS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / therapy. Hemofiltration / methods. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Hydrocortisone / administration & dosage. Hyperuricemia. Kidney Function Tests. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Risk. Survival Analysis. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19030857.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; LMB89 protocol
  •  go-up   go-down


71. Nomura Y, Karube K, Suzuki R, Ying G, Takeshita M, Hirose S, Nakamura S, Yoshino T, Kikuchi M, Ohshima K: High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients. Cancer Sci; 2008 Feb;99(2):246-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients.
  • The aim of the present study was to estimate optimum chemotherapeutic regimens for high-grade mature B-cell lymphoma cases with Burkitt-like morphology (Burkitt's lymphoma [BL]/Burkitt-like lymphoma [BLL]) patients.
  • We analyzed 72 BL/BLL, including 36 with the c-myc translocation (molecular BL [mBL]), 20 without it (mBL-like), and 16 in whom we were uncertain regarding the existence of the c-myc translocation, and compared them with 182 diffuse large B-cell lymphoma (DLBCL) cases.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Female. Humans. Immunohistochemistry. Immunophenotyping. Japan. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18271922.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


72. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol; 2010 Mar;34(3):327-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
  • B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as "double-hit" lymphomas (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, and a spectrum of pathologic features overlapping with Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B-lymphoblastic lymphoma/leukemia (B-LBL).
  • The clinical and pathologic spectrum of this rare entity, including comparison to other high-grade B-cell neoplasms, has not been well defined.
  • Six patients had a history of grade 1 to 2 follicular lymphoma; review of the prior biopsy specimens in 2 of 5 cases revealed blastoid morphology.
  • Twelve DHL cases (60%) were classified as B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL, 7 cases (35%) as DLBCL, not otherwise specified, and 1 case as B-LBL.
  • DHL is a high-grade B-cell neoplasm with a poor prognosis, resistance to multiagent chemotherapy, and clinical and pathologic features distinct from other high-grade B-cell neoplasms.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Regulation, Neoplastic. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Genes, Immunoglobulin Heavy Chain. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Terminology as Topic. Time Factors. Treatment Outcome. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):525-34 [10757399.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1960-6 [11069032.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):52-4 [11120335.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51 [11343778.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):610-3 [12708908.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):474-9 [15239399.001]
  • [Cites] Blood. 1983 Nov;62(5):1142-6 [6605167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70 [6334305.001]
  • [Cites] Am J Clin Pathol. 1986 May;85(5):636-40 [3486584.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] N Engl J Med. 1988 May 26;318(21):1373-8 [3285208.001]
  • [Cites] Oncogene. 1988 May;2(5):431-5 [3131717.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1454-9 [2509518.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Jul;2(2):147-58 [2278969.001]
  • [Cites] Oncogene. 1991 Jan;6(1):145-8 [1992441.001]
  • [Cites] Leukemia. 1991 Jan;5(1):83-7 [1999960.001]
  • [Cites] Leukemia. 1991 Jun;5(6):473-8 [1711639.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Ann Hematol. 1991 Nov;63(5):282-7 [1958753.001]
  • [Cites] Ann Hematol. 1992 Feb;64(2):101-4 [1554791.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leukemia. 1994 Apr;8(4):560-3 [8152251.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):87-94 [8019967.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):55-61 [9541684.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):414-23 [15852472.001]
  • [Cites] Hum Pathol. 2005 May;36(5):571-5 [15948125.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1490-6 [16224216.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2313-23 [16193090.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Nov;171(1):52-6 [17074591.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1061-4 [17182663.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Am J Clin Pathol. 2008 Jan;129(1):157-66 [18089500.001]
  • [Cites] Curr Protoc Hum Genet. 2007 Jan;Chapter 8:Unit 8.8 [18428417.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1593-607 [18753947.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):716-25 [19120369.001]
  • [Cites] Leukemia. 2009 Feb;23(2):225-34 [18923440.001]
  • [Cites] Leukemia. 2009 Apr;23(4):777-83 [19151788.001]
  • [Cites] Haematologica. 2009 Jul;94(7):935-43 [19535347.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • (PMID = 20118770.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R37 CA076404; United States / NIGMS NIH HHS / GM / T32 GM074897; United States / NIGMS NIH HHS / GM / T32 GM074897-07
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ NIHMS305320; NLM/ PMC3152212
  •  go-up   go-down


73. Cogliatti SB, Novak U, Henz S, Schmid U, Möller P, Barth TF, Swiss Group for Clinical Cancer Research (SAKK): Diagnosis of Burkitt lymphoma in due time: a practical approach. Br J Haematol; 2006 Aug;134(3):294-301
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of Burkitt lymphoma in due time: a practical approach.
  • The quick diagnosis of Burkitt lymphoma (BL) and its clear-cut differentiation from diffuse large B-cell lymphoma (DLBCL) is of great clinical importance because treatment strategies for these two disease entities differ markedly.
  • As these two lymphomas are difficult to distinguish using the current World Health Organization classification, we studied 39 cases of highly proliferative peripheral blastic B-cell lymphoma (HPBCL) to establish a practical differential-diagnostic algorithm.
  • Characteristics set for BL were a typical morphology, a mature B-cell phenotype of CD10+, Bcl-6+ and Bcl-2- tumour cells, a proliferation rate of >95%, and the presence of C-MYC rearrangements in the absence of t(14;18)(q32;q21).
  • [MeSH-major] Burkitt Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Female. Gene Rearrangement. Genes, myc. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / mortality. Male. Middle Aged. Neprilysin / analysis. Survival Rate. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848772.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


74. Park YH, Kim WS, Kang HJ, Na II, Ryoo BY, Yang SH, Lee SS, Uhm JE, Kim K, Jung CW, Park K, Ko YH: Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. Ann Hematol; 2006 May;85(5):285-90
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
  • Burkitt lymphoma/leukemia (BL) is a highly aggressive non-Hodgkin's lymphoma (NHL) often presenting in extranodal sites or as an acute leukemia.
  • Because of the shared molecular and genetic features, the World Health Organization classification of lymphoid diseases recognizes the lymphomatous and leukemic phases of BL as a single entity: a mature B cell neoplasm, subtype Burkitt lymphoma/Burkitt cell leukemia.
  • [MeSH-major] Burkitt Lymphoma / mortality. Stomach Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518604.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


75. Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, Stamattoulas A, Dupriez B, Raphaël M, Pico JL, Ribrag V, GELA, GOELAMS: Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol; 2005 Dec;16(12):1928-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
  • BACKGROUND: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia.
  • CONCLUSION: Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284057.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


76. Seegmiller AC, Garcia R, Huang R, Maleki A, Karandikar NJ, Chen W: Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod Pathol; 2010 Jul;23(7):909-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas.
  • Rearrangement of MYC with immunoglobulin genes is a hallmark of Burkitt lymphoma.
  • This study aimed to assess the impact of karyotypic complexity, in correlation with comprehensive immunophenotypic analyses on the diagnosis and clinical outcomes of 34 cases of MYC-IG rearranged lymphomas that included Burkitt lymphoma (twenty-two cases), diffuse large B-cell lymphoma (three cases), unclassifiable B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (six cases), and plasmablastic lymphoma (three cases).
  • Burkitt lymphoma cases had a significantly lower number of additional abnormalities (mean of 1.7), compared with unclassified B-cell lymphoma (3.3), diffuse large B-cell lymphoma (21.7), and plasmablastic lymphoma (6.7).
  • Cases with simple karyotype (< or =2 additional abnormalities) were more likely to have a diagnosis of Burkitt lymphoma (89 versus 33% in patients with >2 additional abnormalities, P<0.01) and express bcl-6 (95 versus 47%, P<0.01).
  • In addition, Burkitt lymphoma, bcl-6 expression, and simple karyotype were individual predictors of better overall survival.
  • We conclude that simple karyotype and bcl-6 expression suggest a diagnosis of Burkitt lymphoma and may portend better overall survival.
  • These results may be very useful in the diagnosis and stratification of MYC-IG rearranged high-grade B-cell lymphomas.
  • [MeSH-major] Burkitt Lymphoma / genetics. DNA-Binding Proteins / biosynthesis. Genes, Immunoglobulin. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Separation. Child. Child, Preschool. Chromosome Aberrations. Female. Flow Cytometry. Gene Rearrangement. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Prognosis. Young Adult

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348878.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


77. Maruyama D, Watanabe T, Maeshima AM, Nomoto J, Taniguchi H, Azuma T, Mori M, Munakata W, Kim SW, Kobayashi Y, Matsuno Y, Tobinai K: Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol; 2010 Dec;92(5):732-43
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
  • The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported.
  • In conclusion, our modified CODOX-M/IVAC regimen is well tolerated and highly effective in Japanese adult patients with BL and intermediate DLBCL/BL, warranting a larger study for confirmation.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):123-32 [1985161.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Cancer Sci. 2008 Sep;99(9):1760-8 [18549405.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):133-8 [1985162.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1072-8 [15205201.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2471-8 [1421370.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Blood. 2009 May 14;113(20):4834-40 [19264918.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):246-52 [18271922.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Int J Hematol. 2008 May;87(4):393-7 [18409079.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3713-20 [11389007.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):59-68 [16831590.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1732-9 [3491184.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):935-40 [8622042.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Int J Hematol. 2008 Nov;88(4):443-7 [18855101.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] J Clin Oncol. 1986 Jun;4(6):847-58 [3711961.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):364-9 [17079695.001]
  • [Cites] Cancer Sci. 2005 Feb;96(2):77-82 [15723651.001]
  • (PMID = 21120644.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


78. Sevilla DW, Gong JZ, Goodman BK, Buckley PJ, Rosoff P, Gockerman JP, Lagoo AS: Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol; 2007 Dec;128(6):981-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation.
  • In the World Health Organization classification, cases with classical Burkitt morphologic features and a very high proliferation fraction but without the MYC translocation are not clearly designated as a separate entity and are usually categorized as diffuse large B-cell lymphoma (DLBCL).
  • We identified from our records 33 cases of highly aggressive mature B-cell neoplasms from 8 children and 25 adults with typical Burkitt cytomorphologic, histologic, and immunophenotypic (CD20+/CD10+ and surface immunoglobulin-positive) features.
  • The immunophenotype of the lymphoma cells in the 2 groups was similar.
  • Although children with MYC+ and MYC- neoplasms were treated with chemotherapy regimens appropriate for Burkitt lymphoma, adults with MYC- lymphomas received less aggressive therapy usually given for DLBCL.
  • Provisional identification of MYC- lymphomas with typical Burkitt morphologic features as an entity separate from DLBCL will facilitate further studies and possible categorization as a separate entity.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / genetics. Genes, myc. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Cell Proliferation. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Immunophenotyping. Male. Middle Aged. Neprilysin / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024324.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


79. Mossafa H, Damotte D, Jenabian A, Delarue R, Vincenneau A, Amouroux I, Jeandel R, Khoury E, Martelli JM, Samson T, Tapia S, Flandrin G, Troussard X: Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk Lymphoma; 2006 Sep;47(9):1885-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis.
  • Out of 344 patients with newly diagnosed non-Hodgkin's lymphoma (NHL), this study identified 16 patients presenting Burkitt-like cells (BLCs) after cytological and/or histological review.
  • The BLCs were present whatever the lymphoma sub-type: follicular lymphoma (FL) was diagnosed in six out of 16 patients, mantle cell lymphoma (MCL) in four out of 16 patients, marginal zone lymphoma (MZL) in two out of 16 patients and diffuse large B-cell lymphomas (DLBCL) in three out of 16 patients.
  • One additional patient presented a T-cell lymphoma.
  • These data could suggest a sub-group of NHL patients (15 B-NHL, 1 T-NHL) have been identified with a poor prognosis characterized by the association of Burkitt-like cells and c-MYC amplification without t(8;14)(q24;q32) or its variants.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Amplification. Lymphoma, T-Cell / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosomes, Human / genetics. Cytogenetic Analysis. Female. Humans. Immunoglobulin Heavy Chains / genetics. In Situ Hybridization, Fluorescence. Karyotyping. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Male. Middle Aged. Prognosis. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065002.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


80. Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, Mbulaiteye SM: AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood; 2010 Dec 16;116(25):5600-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?
  • Trimodal or bimodal age-specific incidence rates for Burkitt lymphoma (BL) were observed in the United States general population, but the role of immunosuppression could not be excluded.
  • Incidence rates, rate ratios, and 95% confidence intervals for BL and other non-Hodgkin lymphoma (NHL), by age and CD4 lymphocyte count categories, were estimated using Poisson regression models using data from the United States HIV/AIDS Cancer Match study (1980-2005).
  • BL incidence was 22 cases per 100 000 person-years and 586 for non-BL NHL.
  • Adjusted BL incidence rate ratio among males was 1.6× that among females and among non-Hispanic blacks, 0.4× that among non-Hispanic whites, but unrelated to HIV-transmission category.
  • Non-BL NHL incidence increased from childhood to adulthood; in contrast, 2 age-specific incidence peaks during the pediatric and adult/geriatric years were observed for BL.
  • Non-BL NHL incidence rose steadily with decreasing CD4 lymphocyte counts; in contrast, BL incidence was lowest among people with ≤ 50 CD4 lymphocytes/μL versus those with ≥ 250 CD4 lymphocytes/μL (incidence rate ratio 0.3 [95% confidence interval = 0.2-0.6]).
  • The bimodal peaks for BL, in contrast to non-BL NHL, suggest effects of noncumulative risk factors at different ages.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Jan 15;93(2):758 [10215347.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1124 [10025990.001]
  • [Cites] Cancer. 1957 Sep-Oct;10(5):1045-54 [13472655.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] Oncologist. 2006 Apr;11(4):375-83 [16614233.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Jun 2;55(21):589-92 [16741494.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Immunity. 2007 Aug;27(2):190-202 [17723214.001]
  • [Cites] AIDS. 2007 Nov 12;21(17):2265-70 [18090274.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2658-63 [18767045.001]
  • [Cites] Int J Cancer. 2009 Apr 1;124(7):1497-502 [19089924.001]
  • [Cites] Int J Cancer. 2009 Apr 15;124(8):1745-55 [19165855.001]
  • [Cites] Curr Opin HIV AIDS. 2009 May;4(3):183-7 [19532048.001]
  • [Cites] PLoS Med. 2009 Jul 7;6(7):e1000107 [19582166.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):366-70 [19434731.001]
  • [Cites] Semin Cancer Biol. 2009 Dec;19(6):347-50 [19607918.001]
  • [Cites] Int J Cancer. 2010 Apr 1;126(7):1732-9 [19810101.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Am J Med. 2001 Dec 15;111(9):704-11 [11747850.001]
  • [Cites] Ann Intern Med. 1969 Apr;70(4):817-32 [4306129.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18470-6 [10373455.001]
  • [Cites] Nature. 1972 May 5;237(5349):33-4 [4113130.001]
  • [Cites] Eur J Cancer. 1972 Jun;8(3):305-8 [4677829.001]
  • [Cites] J Natl Cancer Inst. 1974 May;52(5):1397-401 [4406651.001]
  • [Cites] IARC Sci Publ. 1985;(60):217-24 [4065946.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1987 Dec 25;36 Suppl 7:1S-20S [2826984.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9838-42 [1682922.001]
  • [Cites] Nature. 1993 Mar 25;362(6418):355-8 [8455722.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1099-107 [8099121.001]
  • [Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]
  • [Cites] Stat Med. 1995 Mar 15-Apr 15;14(5-7):491-8 [7792443.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6577-81 [7604036.001]
  • [Cites] Prev Med. 1995 Jul;24(4):375-7 [7479628.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [CommentIn] Blood. 2010 Dec 16;116(25):5435-6 [21163931.001]
  • (PMID = 20813897.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CP / N02CP31003; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3031406
  •  go-up   go-down


81. Alonso-Pérez A, Fraga J, Delgado Y, Aragüés M, Nam-Cha S, García-Díez A: Nodular herpes zoster with herpetic syringitis and no epidermal involvement in a patient with Burkitt lymphoma. Am J Dermatopathol; 2006 Jun;28(3):194-6
HIV InSite. treatment guidelines - HIV InSite .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular herpes zoster with herpetic syringitis and no epidermal involvement in a patient with Burkitt lymphoma.
  • We report the case of a woman with Burkitt lymphoma who developed 2 nodular, asymptomatic lesions while receiving treatment with chemotherapy and radiotherapy for her hematological disease.
  • [MeSH-major] Burkitt Lymphoma / pathology. Eccrine Glands / pathology. HIV Infections / pathology. Herpes Zoster / pathology. Herpesvirus 3, Human. Skin Diseases, Viral / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Dermis / pathology. Dermis / virology. Epidermis / pathology. Epidermis / virology. Epithelium / pathology. Epithelium / virology. Female. Humans

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Shingles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778483.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Degeorges S, Mesnil A, Marion-Audibert AM, Bouafia-Sauvy F, Berger F, Bancel B, Barnoud R, Rode A, Péré-Vergé D, Souquet JC: [Ano-rectal symptoms, related to Epstein-Barr Virus-Associated Burkitt's lymphoma in an immunocompetent patient]. Gastroenterol Clin Biol; 2007 Apr;31(4):442-4
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ano-rectal symptoms, related to Epstein-Barr Virus-Associated Burkitt's lymphoma in an immunocompetent patient].
  • [Transliterated title] Manifestations anorectales, en rapport avec un lymphome de Burkitt associé au virus Epstein Barr, chez une malade immunocompétente.
  • Final diagnosis confirmed by biopsy performed during rectosigmoidoscopy was an Epstein-Barr Virus-Associated Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Female. Humans. Immunocompetence. Magnetic Resonance Imaging. Rectum / pathology. Sigmoidoscopy. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483786.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


83. Gualco G, Queiroga EM, Weiss LM, Klumb CE, Harrington WJ Jr, Bacchi CE: Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma. Hum Pathol; 2009 Apr;40(4):565-71
Genetic Alliance. consumer health - Multiple myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma.
  • Burkitt lymphoma is a highly aggressive non-Hodgkin lymphoma with endemic, sporadic, and immunodeficiency-associated clinical variants composed of monomorphic medium-sized B cells with a high proliferation rate and a translocation involving the C-MYC locus.
  • Classically, the immunophenotype of Burkitt lymphoma has been considered to be the germinal center type.
  • In most reports, all cases of Burkitt lymphoma are reported to be multiple myeloma 1-negative. multiple myeloma 1 expression is seen in plasma cells and in a small fraction of B cells located in the light zone of germinal centers corresponding to the final step of intra-germinal center B-cell differentiation, and in activated T cells.
  • Therefore, multiple myeloma 1 expression may denote the final step of intra-germinal center B-cell differentiation at the centrocyte stage, as well as the subsequent steps of B-cell maturation toward plasma cells.
  • Twenty-five Burkitt lymphoma cases, including 19 associated with HIV, were reported in one of the few studies in the literature; 2 of these cases showed occasional multiple myeloma 1-positive cells, less than the 20% cutoff for positivity.
  • We studied 222 cases of well-characterized Burkitt lymphoma with the classic phenotype and C-MYC translocation and found 90 cases (40.5%) with multiple myeloma 1 nuclear expression, suggesting a late germinal center stage of differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Am J Clin Pathol. 2008 Dec;130(6):946-56 [19019773.001]
  • [Cites] Leukemia. 2000 Apr;14(4):563-6 [10764139.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):247-57 [11091208.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):686-94 [11455001.001]
  • [Cites] Blood. 2002 Jan 15;99(2):409-26 [11781220.001]
  • [Cites] Br J Haematol. 2002 May;117(2):366-72 [11972519.001]
  • [Cites] Med Sci Monit. 2003 Jan;9(1):HY1-9 [12552250.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):384-92 [15023043.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Science. 1997 Jan 24;275(5299):540-3 [8999800.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):226-30 [9326949.001]
  • [Cites] Cytokine Growth Factor Rev. 1997 Dec;8(4):293-312 [9620643.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):790-8 [16203284.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Oncologist. 2006 Apr;11(4):375-83 [16614233.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2495-8 [16760450.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):315-9 [16896892.001]
  • [Cites] Adv Anat Pathol. 2007 Jan;14(1):25-35 [17198308.001]
  • [Cites] Haematologica. 2007 Feb;92(2):267-8 [17296585.001]
  • [Cites] Am J Clin Pathol. 2007 Oct;128(4):558-64 [17875505.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1343-50 [17768115.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • [Cites] Leukemia. 2000 Mar;14(3):449-56 [10720141.001]
  • (PMID = 19144381.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / 5U01CA121947; United States / NCI NIH HHS / CA / CA121947-03; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / U01 CA121947-03; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / 5R01CA121935
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Syndecan-1; 0 / interferon regulatory factor-4
  • [Other-IDs] NLM/ NIHMS125062; NLM/ PMC2741026
  •  go-up   go-down


84. Kojima M, Sakurai S, Morita Y, Nakamura N, Sugihara S, Shimano S: EBV(+) B-cell lymphoproliferative disorder associated with subsequent development of Burkitt lymphoma in a patient with idiopathic CD4(+) T-lymphocytopenia. J Clin Exp Hematop; 2008 Nov;48(2):55-9
Genetic Alliance. consumer health - T-Lymphocytopenia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV(+) B-cell lymphoproliferative disorder associated with subsequent development of Burkitt lymphoma in a patient with idiopathic CD4(+) T-lymphocytopenia.
  • We report here a case of idiopathic CD4(+) T-lymphocytopenia (ICL) associated with Epstein-Barr virus (EBV)(+) lymphoproliferative disorder (LPD) terminating in Burkitt lymphoma (BL).
  • Biopsy of the specimen showed reactive lymph node hyperplasia and interfollicular B-cell hyperplasia.
  • [MeSH-major] Burkitt Lymphoma / virology. Epstein-Barr Virus Infections / pathology. Lymphoproliferative Disorders / virology. T-Lymphocytopenia, Idiopathic CD4-Positive / pathology
  • [MeSH-minor] Adult. B-Lymphocytes / pathology. Biopsy. Flow Cytometry. Genes, Immunoglobulin Heavy Chain. Herpesvirus 4, Human / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Lymph Nodes / pathology. Male. Nose Neoplasms / pathology. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19039197.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. Lamvik J, Waage A, Wahl SG, Naess I, Paulsen PQ, Hammerstrøm J: Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004. Haematologica; 2006 Oct;91(10):1428-9
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004.
  • We report a population-based investigation on adult acute precursor B lymphoblastic leukemia, Burkitt's lymphoma and T lymphoblastic lymphoma in a defined geographic area.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Hematopoietic Stem Cells / pathology. Humans. Incidence. Male. Middle Aged. Norway / epidemiology


86. Bellier C, Khellaf M, Lambotte O, Godeau B: [Burkitt's lymphoma in a patient with systemic lupus erythematosus treated with immunosuppressive drugs. A case report]. Rev Med Interne; 2006 Mar;27(3):244-7
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Burkitt's lymphoma in a patient with systemic lupus erythematosus treated with immunosuppressive drugs. A case report].
  • [Transliterated title] Lymphome de Burkitt au cours d'un lupus systémique traité par immunosuppresseurs. A propos d'un cas.
  • However, the pathophysiological link between lymphoma and SLE is still a matter of debate.
  • We report a new case of Burkitt's lymphoma occurring in a patient treated with immunosuppressive drugs for SLE.
  • A bone marrow biopsy revealed Burkitt's lymphoma.
  • CONCLUSION: This is the third case reported of Burkitt's lymphoma occurring in SLE.
  • Here we discuss the data of the literature and the possible pathophysiological links between Burkitt's lymphoma and SLE.


87. Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gérard L, Oksenhendler E: Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood; 2007 Oct 15;110(8):2846-54
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
  • Prognosis of acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma has improved since the introduction of highly active antiretroviral therapy.
  • Burkitt lymphomas (BLs) still have poor outcome in patients with bone marrow (BM) or central nervous system (CNS) involvement when treated with standard-dose chemotherapy.
  • At BL diagnosis, the median CD4 cell count was 239 x 10(6)/L (range, 16-1188 x 10(6)/L).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Prospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609431.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


88. Patte C, Ribrag V, Brugières L: [Non Hodgkin's lymphoma in adolescents]. Bull Cancer; 2007 Apr;94(4):339-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's lymphoma in adolescents].
  • [Transliterated title] Problématique de la prise en charge des adolescents atteints de lymphomes non hodgkiniens.
  • In France, adolescents (15-20 years) with non Hodgkin's lymphoma (NHL) are referred either to paediatric or to adult onco-haematological departments.
  • The categories of NHL that are reviewed and whose clinical and biological characteristics are presented are: Burkitt, lymphoblastic and large cell, either B or anaplastic.
  • Further studies specific to the adolescents are needed to better know the biology of their lymphoma and to determine the best therapeutic approach.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Child. Clinical Protocols. France / epidemiology. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Medical Oncology / organization & administration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449436.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 72
  •  go-up   go-down


89. Nelson M, Perkins SL, Dave BJ, Coccia PF, Bridge JA, Lyden ER, Heerema NA, Lones MA, Harrison L, Cairo MS, Sanger WG: An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. Br J Haematol; 2010 Feb;148(4):600-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.
  • Burkitt lymphoma (BL), an aggressive B-cell malignancy, is often curable with short intensive treatment regiments.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1981 Jun;3(4):307-15 [7260888.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Ann Genet. 1989;32(1):26-32 [2751244.001]
  • [Cites] Cytogenet Cell Genet. 1989;52(3-4):136-8 [2630185.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Nov;1(2):115-8 [2487150.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Oct 1;63(1):22-4 [1423221.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6547-52 [1330296.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Apr;6(4):199-205 [7685621.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):282-7 [7519050.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2463-73 [9395242.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):1-19 [9720711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1084-92 [16862570.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):840-7 [18371107.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1925-30 [10706856.001]
  • [Cites] Blood Rev. 2001 Mar;15(1):49-59 [11333138.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5595-610 [11607812.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9 [12808131.001]
  • [Cites] Eur J Haematol. 2003 Sep;71(3):179-83 [12930318.001]
  • [Cites] Leukemia. 2003 Oct;17(10):2016-24 [14513052.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):10-8 [15034863.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Mar;26(3):169-78 [15125609.001]
  • [Cites] J Pathol. 2004 Aug;203(4):940-5 [15258997.001]
  • [Cites] Leuk Lymphoma. 2004 May;45(5):965-9 [15291356.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1595-603 [15370211.001]
  • [Cites] Int J Cancer. 1977 Apr 15;19(4):482-6 [844916.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Leukemia. 2009 Feb;23(2):323-31 [19020548.001]
  • [Cites] Eur J Cancer. 1981 May;17(5):577-84 [6271555.001]
  • (PMID = 19895612.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098543-01
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS163764; NLM/ PMC2921871
  •  go-up   go-down


90. Burmeister T, Macleod RA, Reinhardt R, Mansmann V, Loddenkemper C, Marinets O, Drexler HG, Thiel E, Blau IW: A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique t(6;20)(q15;q11.2) rearrangement. Leuk Res; 2006 Nov;30(11):1417-23
Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique t(6;20)(q15;q11.2) rearrangement.
  • We report the establishment and characterization, including HLA-typing, immunophenotypic and molecular cytogenetic analysis, of a novel EBV-negative cell line (BLUE-1) derived from adult relapsed sporadic Burkitt lymphoma.
  • BLUE-1 carries the pathognomonic t(8;14)(q24;q32) effecting MYC/IgHJ fusion and a novel t(6;20)(q15;q11.2) originally present in the patient, analysis of which may facilitate identification of gene target(s) of recurrent 6q rearrangements in B-cell neoplasia.
  • Our findings are discussed in light of the current understanding of endemic and sporadic Burkitt lymphoma.
  • BLUE-1 grows well in culture and should be a useful lymphoma research tool.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Line, Tumor. Chromosomes, Human, Pair 20 / genetics. Chromosomes, Human, Pair 6 / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Cytogenetic Analysis / methods. HLA Antigens / genetics. Histocompatibility Testing. Humans. Immunohistochemistry. Immunophenotyping. Male. Oligonucleotide Array Sequence Analysis / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697040.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


91. Chuang SS, Ye H, Du MQ, Lu CL, Dogan A, Hsieh PP, Huang WT, Jung YC: Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH. Am J Clin Pathol; 2007 Oct;128(4):558-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH.
  • Burkitt lymphoma (BL) is characterized by c-myc translocation and CD10+/bc-2-/bcl-6+ with a very high Ki-67 proliferation index (PI).
  • Occasional diffuse large B-cell lymphomas may exhibit a very high PI with or without a starry-sky pattern (DLBCL-HPSS).
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Cell Proliferation. In Situ Hybridization, Fluorescence. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. RNA, Viral / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Child. Child, Preschool. Diagnosis, Differential. Female. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. Immunophenotyping. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875505.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral
  •  go-up   go-down


92. Jarrett RF: Viruses and lymphoma/leukaemia. J Pathol; 2006 Jan;208(2):176-86
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viruses and lymphoma/leukaemia.
  • The human T-cell leukaemia virus type 1 causes adult T-cell leukaemia and the Epstein-Barr virus is associated with Burkitt's lymphoma, lymphomas in immunosuppressed people, and Hodgkin lymphoma.
  • Individuals infected with the human immunodeficiency virus are at greatly increased risk of developing lymphoma but here the mechanism of lymphomagenesis is indirect.
  • Recent data suggest that hepatitis C virus infection is also associated with an increased incidence of lymphoma, whereas data relating to SV40 remain controversial.
  • [MeSH-major] Leukemia / virology. Lymphoma / virology
  • [MeSH-minor] Adult. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. Burkitt Lymphoma / virology. HIV / immunology. Hepacivirus / immunology. Herpesvirus 1, Cercopithecine / immunology. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / immunology. Hodgkin Disease / genetics. Hodgkin Disease / immunology. Hodgkin Disease / virology. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / immunology. Humans. Simian virus 40 / immunology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [CommentIn] J Pathol. 2006 Jul;209(3):420-1; author reply 422-4 [16639695.001]
  • (PMID = 16362996.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 105
  •  go-up   go-down


93. Boerma EG, Siebert R, Kluin PM, Baudis M: Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia; 2009 Feb;23(2):225-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge.
  • Burkitt lymphoma (BL) has a characteristic clinical presentation, morphology, immunophenotype and primary chromosomal aberration, that is, the translocation t(8;14)(q24;q32) or its variants.
  • However, diagnostic dilemmas may arise in daily practice due to overlap of BL with subsets of other aggressive, mature B-cell lymphomas such as diffuse large B-cell lymphomas (DLBCL).
  • Within the core subset, no differences were found between pediatric and adult patients.
  • We suggest that, concordant with the WHO classification to be published in 2008, the diagnosis of BL should be restricted to cases with expression of CD10 and BCL6, absence or very weak expression of BCL2 protein, a homogeneously very high proliferation index and a proven IG-MYC translocation without evidence of a chromosomal translocation typical for other lymphoma entities.
  • [MeSH-major] Burkitt Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Chromosomes, Human, Pair 8. Cytogenetics / history. Gene Expression Profiling. History, 20th Century. History, 21st Century. Humans. Lymphoma / classification. Lymphoma / diagnosis. Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18923440.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 59
  •  go-up   go-down


94. Bariakh EA, Zvonkov EE, Kremenetskaia AM, Kravchenko SK, Magomedova AU, Obukhova TN, Samoĭlova RS, Vorob'ev IA, Kaplanskaia IB, Moiseeva TN, Zybunova EE, Lorie IuIu, Chernova NG, Mar'in DS, Egorova EK, Krasil'nikova BB, Gabeeva NG, Vorob'ev AI: [Treatment of adult Berkitt-like lymphoma]. Ter Arkh; 2005;77(7):53-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of adult Berkitt-like lymphoma].
  • AIM: To compare programs of chemotherapy used in adult Berkitt-like lymphoma (ABLL); to assess efficacy and toxicity of the protocol AblL-M-04.
  • 10 patients had diffuse large B-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Adult. Asparaginase / therapeutic use. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Disease Progression. Dose-Response Relationship, Drug. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Prednisolone / therapeutic use. Prednisone / therapeutic use. Retrospective Studies. Severity of Illness Index. Time Factors. Treatment Outcome. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116910.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; CHOP protocol; PVDA protocol; non-Hodgkin's lymphoma protocol 8503
  •  go-up   go-down


95. Pezzolo A, Cinti R, Negri F, Parodi F, Garaventa A, Gambini C, Pistoia V: Chromosomal imbalances in pediatric Burkitt-like lymphoma and review of the literature in relation to other germinal center derived B-cell tumors. Leuk Lymphoma; 2006 Nov;47(11):2359-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal imbalances in pediatric Burkitt-like lymphoma and review of the literature in relation to other germinal center derived B-cell tumors.
  • This study reports on the cytogenetic features of a novel case of pediatric Burkitt-like lymphoma (BLL), that adds to the three published.
  • (1) imbalances shared by most germinal center (GC) derived B-cell tumors including BLL (+1q, -6q, -8p, +8q24 and +11);.
  • (2) imbalances already reported in adult but not in pediatric BLL cases and shared with most GC B-cell tumors (+7, -9p, -9q, +12q, -13q, +17, +19, -3 and -4);.
  • (3) imbalances already reported in pediatric but not in adult BLL cases and shared with some GC B-cell tumors (-2q); and (4) imbalances never described before in pediatric or adult BLL, but present in different GC B-cell tumors (-6p, -1p and -18q).
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / pathology. Chromosomes, Human / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107910.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


96. Fayad L, Thomas D, Romaguera J: Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma; 2007 Dec;8 Suppl 2:S57-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
  • Mantle cell lymphoma (MCL) and Burkitt lymphoma respond to initial intense therapies, such as hyper-CVAD (hyperfractionated cyclophosphamide/vincristine/doxorubicin/dexamethasone) alternating with high-dose methotrexate/cytarabine, to which the monoclonal antibody rituximab has recently been added.
  • This report provides an update detailing the long-term outcome when this chemoimmunotherapy regimen is used as first-line therapy for newly diagnosed MCL, de novo Burkitt lymphoma, atypical Burkitt lymphoma, and mature B-cell acute lymphoblastic lymphoma (B-ALL).
  • Ninety-seven patients with de novo MCL and 31 patients with Burkitt lymphoma, atypical Burkitt lymphoma, and B-ALL were treated with rituximab plus hyper-CVAD alternating with rituximab/methotrexate/cytarabine under different institutional trials approved by the University of Texas M. D.
  • Overall RR for patients with Burkitt lymphoma/atypical Burkitt lymphoma/B-ALL was 97% (CR rate, 86%).
  • Rituximab plus hyper-CVAD alternating with rituximab/methotrexate/cytarabine is an effective dose-intense chemoimmunotherapy program for untreated MCL, Burkitt lymphoma, atypical Burkitt lymphoma, and B-ALL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Rituximab. Survival Rate. Texas. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284717.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


97. Gutiérrez-García L, Medina Ramos N, García Rodríguez R, Barber MA, Arias MD, García JA: Bilateral ovarian Burkitt's lymphoma. Eur J Gynaecol Oncol; 2009;30(2):231-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ovarian Burkitt's lymphoma.
  • Primary ovarian lymphoma is a rare entity.
  • Histology confirmed Epstein-Barr virus-positive bilateral Burkitt's lymphoma.
  • Endemic Burkitt's lymphoma has a predilection for the female genital tract, manifesting itself clinically as a pelvic mass and less frequently as a menstrual disorder.
  • [MeSH-major] Burkitt Lymphoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Herpesvirus 4, Human / isolation & purification. Humans

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480266.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


98. Suzuki K, Nakazato T, Sanada Y, Mihara A, Tachikawa N, Kurai H, Yoshimura Y, Hayashi H, Yoshida S, Kakimoto T: [Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma]. Rinsho Ketsueki; 2010 Mar;51(3):207-12
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma].
  • Colonoscopy was performed and histological examination of the colon tumor revealed Burkitt's lymphoma (BL).
  • In the HAART era, the survival of patients with AIDS-related diffuse large cell lymphoma (DLCL) improved dramatically, whereas the survival of similarly treated patients with AIDS-related BL remained poor.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / drug therapy. Colonic Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379116.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CVAD protocol; EPOCH protocol
  •  go-up   go-down


99. Bellan C, Lazzi S, Hummel M, Palummo N, de Santi M, Amato T, Nyagol J, Sabattini E, Lazure T, Pileri SA, Raphael M, Stein H, Tosi P, Leoncini L: Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood; 2005 Aug 1;106(3):1031-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas.
  • The normal counterpart of the neoplastic B cells in Burkitt lymphoma (BL) is still unclear.
  • However, most of these studies rely on cell lines or on a small series of cases.
  • To help clarify the cell of origin of BL, semi-nested polymerase chain reaction (PCR) was performed to amplify the VDJ rearrangements of the immunoglobulin heavy chain (V(H)) genes, and the resultant amplificates were sequenced for comparison with known germline V(H) segments.
  • The different types of C-MYC translocation reported in BL may also be related to the different stages of B-cell maturation.
  • [MeSH-major] Burkitt Lymphoma / pathology. Burkitt Lymphoma / virology. Genes, Immunoglobulin. Herpesvirus 4, Human
  • [MeSH-minor] Adolescent. Adult. Aged. B-Lymphocytes / pathology. Child. Child, Preschool. Gene Rearrangement. Germinal Center / pathology. Humans. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / genetics. Middle Aged. Mutation. Polymerase Chain Reaction. Sequence Analysis, DNA

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840698.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


100. Chen SW, Chang ST, Lu CL, Hwang WS, Tsao CJ, Huang WT, Chang KY, Chuang SS: Upper aerodigestive tract lymphoma in Taiwan. J Clin Pathol; 2010 Oct;63(10):888-93
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper aerodigestive tract lymphoma in Taiwan.
  • AIM: To better understand the spectrum of primary lymphomas in the upper aerodigestive tract, a common site of extranodal lymphoma.
  • MATERIALS AND METHODS: Lymphoma cases diagnosed at an institution in southern Taiwan from 1992 to 2007 were retrospectively studied with pathology and history review, immunohistochemistry, in situ hybridisation for Epstein-Barr virus (EBER-ISH), and statistical analysis.
  • Phenotypically, there were 45 (64%) B cell and 25 (36%) T cell or extranodal natural killer (NK)/T cell lymphoma (ENKL) including 42 (60%) diffuse large B cell lymphomas (DLBCLs), 22 (31%) ENKLs, three unspecified peripheral T cell lymphomas, two follicular lymphomas and one Burkitt lymphoma.
  • The 5-year overall survival for all patients was 56.3% with B and T or NK/T cell lymphomas at 66.0% and 40.6%, respectively.
  • Univariate analysis revealed that sinonasal presentation, T or NK/T cell phenotype, raised lactate dehydrogenase (LDH) activity, and Ann Arbor stage III/IV diseases were associated with prognostically significant higher hazard ratio (HR) of lymphoma-related death.
  • CONCLUSIONS: Only a limited number of lymphoma entities occurred primarily in this anatomical region.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Child. Epidemiologic Methods. Epstein-Barr Virus Infections / complications. Female. Humans. L-Lactate Dehydrogenase / blood. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Lymphoma, T-Cell / virology. Male. Middle Aged. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Mouth Neoplasms / virology. Neoplasm Staging. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876320.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down






Advertisement